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Short Summary 
Transcutaneous vaccination refers to the needle-free delivery of vaccines across 
the skin. In particular, transfollicular vaccination aims to deliver antigens to the 
abundant peri-follicular antigen presenting cells. Many of the studies conducted to 
date to explore this route have been done after pre-treating the skin using 
techniques such as tape stripping.  
The presented work evaluates the potential of the transfollicular route as a 
perspective for transcutaneous vaccination using nanoparticles (NPs) without 
compromising the stratum corneum barrier by any pre-treatment. The results 
presented in this thesis showed that the model antigen ovalbumin can be delivered 
via the transfollicular route by encapsulating into polymeric NPs (polylactic-co-
glycolide (PLGA) and Chitosan-PLGA), and that immunization by this route is able 
to elicit the same proliferation of antigen-specific CD4+ T cells as an intramuscular 
injection of ovalbumin in an adoptive transfer mouse model. Moreover, immune 
responses generated by this pathway using a conventional mouse model 
demonstrated that inclusion of an adjuvant (bis-(3',5')-cyclic adenosine 
monophosphate, c-di-AMP) in the NP formulation is essential to evoke efficient 
humoral as well as cellular immune responses. Furthermore, a new particulate 
carrier system (inverse micelles sugar glass NPs) was prepared, which allowed 
co-encapsulation of adjuvant and antigen, and showed enhanced stability of 
encapsulated antigen, better follicular uptake, as well as efficient transfollicular 
vaccination.   
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Kurzzusammenfassung  
Transkutane Impfungen ermöglichen eine nadelfreie Anwendung von Impfstoffen. 
Insbesondere die transfollikuläre Vakzinierung erlaubt es, Antigene direkt zu den 
antigen-präsentierenden Zellen im perifollikulären Bereich zu bringen. 
Bei der überwiegenden Zahl bisheriger Studien wurden die Formulierungen auf 
vorbehandelter Haut (z.B. tape stripping) eingesetzt.  
Ziel der vorliegenden Arbeit war es, das Potenzial nanopartikulärer 
Arzneistoffträgersysteme mittels transkutaner Vakzinierung ohne Vorbehandlung 
der Haut über die transfollikuläre Route zu untersuchen. 
In den vorgestellten Studien wurde das Modell-Antigen Ovalbumin in nanoskalige 
Trägersysteme, bestehend aus Polylactid-co-Glycolid- (PLGA) bzw. Chitosan-
PLGA, verkapselt. Kutan verabreicht, zeigten diese in einem adoptiven 
Transfermodel der Maus, dass die Proliferation von antigenspezifischen CD4+ T-
Zellen im gleichen Maße hervorgerufen wird wie durch eine klassische 
intramuskuläre Injektion. Zusätzlich konnte in einem Mausmodel gezeigt werden, 
dass der Zusatz des Adjuvants (bis-(3',5')-cyclo-Adenosin-Monophosphat, c-di-
AMP) zur Arzneistoffträgerformulierung notwendig ist, um eine ausreichende 
humorale und zelluläre Immunstimulierung hervorzurufen. 
Neuartige Carriersysteme in Form von glasartigen inversen Mizellen verbesserten 
die Stabilität des verkapselten Modelantigens, ermöglichten die Co-Verkapslung 
des Adjuvants, sowie auch die follikuläre Aufnahme und damit eine effiziente 
transfollikuläre Vakzinierung. 
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1.1. Transcutaneous vaccination using particle based formulations: 
State of the art  
Infectious diseases impose a serious threat to public health worldwide. Among the 
strategies to fight infections only vaccination has the potential to eradicate the 
disease (the World Health Organization, WHO, certified the eradication of 
smallpox in 1979). New, safe, efficient, and cheap vaccination strategies are 
desperately needed to meet the needs of a growing population in developing 
countries as well as the challenges of fast spreading infectious diseases due to 
global traffic (e.g. 2009 swine flu pandemics).  
Particle based vaccine formulations for TCI address several key issues in 
vaccination today. First of all TCI has been shown to induce superior immune 
responses as compared to systemic vaccines and to hold the potential to convey 
mucosal immunity. This is highly desirable to prevent microbial pathogens from 
entering the body through mucosal surfaces and thus block disease at a very early 
stage. This will also help to reduce the risk of horizontal transmission from infected 
individuals to susceptible hosts.  
Many of the current strategies for TCI (e.g. micro-needles, Gene gun, PowderJect, 
skin abrasion), reduce the protective SC barrier for a significant time to facilitate 
the absorption of the vaccine. This makes them suboptimal for mass vaccination 
campaigns under critical hygienic conditions. Particle based formulations are an 
interesting alternative to this. Needle free strategies are at the forefront to combat 
vaccination related transmitted diseases due to sharing of needles or needle stick 
accidents.  
Over the past decade, particulate carriers have emerged as an attractive delivery 
strategy for antigens and adjuvants. Particle based formulations combine several 
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desirable aspects which make them very attractive for antigen encapsulation. 
Vaccine antigens are often difficult biological entities, including DNA, peptides, 
proteins, attenuated viruses, microorganism fragments. (Nano)encapsulation can 
improve the stability, facilitate absorption and also increase antigenicity by 
mimicking the size of microorganisms. 
The co-delivery of adjuvants is tantamount to increase the immunogenicity of the 
antigen and may allow a reduction of the antigen dose. In the context of 
vaccination so-called dose sparing allows reaching more people when limited 
amount of vaccine antigen is available such as in global pandemics. Furthermore, 
vaccines with higher efficiency are also needed to enable protection of 
immunosuppressed and elderly patients. Importantly, by choosing the right 
adjuvant it is possible to polarize the immune response in a predetermined 
direction and convey mucosal immunity.  
However, until now TCI using particle based vaccine formulations has made no 
impact on medical practice. One of the main difficulties is that NPs cannot 
penetrate the skin to an extent that would allow the application of the required 
dose of antigen. This is due to the formidable stratum corneum (SC) barrier, the 
limited amount of antigen in the formulation and often an insufficient 
immunogenicity. A multitude of strategies are currently under investigation to 
overcome these issues.  
We highlight selected methods presenting a spectrum of solutions ranging from 
transfollicular delivery, to devices disrupting the SC barrier and the combination of 
particle based vaccines with adjuvants discussing their advantages and 
shortcomings. Some of these are currently at an experimental state while others 
are already in clinical testing. All methods have been shown to be capable of 
transcutaneous antigen delivery. 
Introduction 
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1.1.1. Absorption Routes of Nanoparticles Applied to the Skin 
One of the main challenges in TCI is that the vaccine antigens need to overcome 
the SC barrier in order to reach the Langerhans cells (LCs) in the epidermis which 
act as antigen presenting cells (APCs). Intact human skin is widely impermeable to 
solid NPs and MPs. Ultra-flexible liposomes are an exception to this rule. Due to 
the addition of edge activators such as surfactants and/or ethanol they are able to 
change shape and squeeze through the lipid channels of the SC, supposedly 
following an osmotic gradient [1, 2]. Ultra-flexible liposomes have been used 
foremost for encapsulating protein antigens [3, 4]. By including positively charged 
lipids in the formulation they become amenable to complexing nucleotide based 
drugs and thus may be an alternative for DNA vaccination [5-7]. For a more 
extensive overview the reader is referred to some recent reviews [8, 9]. 
Furthermore, ultra-small NPs with sizes less than 10 nm can enter the SC to a low 
and highly variable extent [10]. The toxicity and lack of biodegradability of quantum 
dots, metal or metal oxide NPs notwithstanding, ultra-small NPs are not suitable 
for drug delivery and vaccination purposes due to the extremely small amount of 
drug or antigen which can be loaded onto these particles. Also due to their low and 
variable degree of penetration such formulations would probably require some 
active means of penetration enhancement to enable delivery of a suitable dose. 
 
1.1.2. Nanoparticles for Transfollicular Vaccination 
Polymeric NPs as well as lipid carriers which are often in the size range of a few 
100 nm are especially interesting delivery systems for the purpose of TCI. 
Nonflexible NPs which are applied onto the skin migrate into the hair follicle 
openings by a size-selective mechanism (Fig. 1A) [11]. The hair follicle is a 
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promising target for TCI without compromising the skin barrier [12]. Interestingly, 
the transfollicular route is a common pathway for the invasion of allergens such as 
pollen grains [13]. First evidence for the importance of the transfollicular route for 
transcutaneous vaccine delivery came from differences observed between hairy 
and nude mice [14]. At least for DNA vaccines the hair cycle state also seems to 
determine the successful transfection [15]. Inside the hair follicles antigen uptake 
by the rich pool of peri-follicular antigen presenting cells (APCs) is facilitated due 
to the absence of a SC barrier in the lower follicular orifice [16]. Therefore this 
delivery strategy does not require application of any further measures which would 
reduce the skin barrier. It seems that transfollicular delivery elicits a CD8+ biased 
response which is recommendable for combating intracellular microbes and 
developing vaccines against cancer and virus infections [17]. We showed that 
transfollicular delivery of the nano-encapsulated model antigen ovalbumin (OVA) 
elicited similar proliferation of OVA specific CD4+ T cells as an intra-muscular 
(i.m.) injection of the same dose of soluble antigen in an adoptive transfer model 
[12]. Nano-encapsulation into polymeric NPs improved the delivery of OVA into the 
hair follicles on excised pig ears by a factor of 2.5–3 compared with OVA in 
solution and protected OVA from cleavage or aggregation so that it maintained its 
biological activity to a high degree during storage and shipping [12]. As an 
important outcome of the study we observed in vitro as well as in vivo an intrinsic 
adjuvanticity of the NPs which was also influenced by the polymer material used 
[12]. The effect can probably be enhanced and directed by the combination or co-
encapsulation of adjuvants into the formulation. As hair follicles cover only 0.1% of 
the skin surface trans-follicular delivery has long been discussed to be negligible. 
It was demonstrated however that the capacity of hair follicles is similar to that of 
the SC [18]. Lademann et al. showed that NPs penetrated more efficient into the 
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hair follicles than solutions and form a depot in the follicle that persists for more 
than one week [19]. Still a big issue with transfollicular application is the loss of 
formulation on the skin surface. Consequently a higher amount of vaccine would 
be required to achieve delivery of the required dose, which will need to be 
optimized in the future to make transfollicular vaccination a real alternative.  
1.1.3. Facilitated Absorption Methods 
Particle based vaccines benefit from any form of skin pre-treatment which reduces 
or removes the SC or any mechanical or electrical application method which 
transfers them into the epidermis by force (for review see also ref. [20]). Occlusion 
or chemical penetration enhancers, while enhancing permeation of molecules by 
several folds due to influencing molecular partition and/or diffusion coefficients, 
have very little effect on the permeability of particles [21]. Apart from facilitating 
invasion the barrier disruption additionally causes a non-specific 
immunostimulation [22]. Often these facilitating methods require special devices. 
Important points to consider in this context include (1) cost for devices, (2) ease 
and reproducibility of use also by non-trained personnel (e.g., in a pandemic or for 
mass vaccination in developmental countries lacking medical infrastructure), (3) 
severity and area of barrier disruption, time scale of barrier recovery which are 
connected to the risk of invasion of pathogens through the superficial wound. The 
severity of these issues varies depending on the type of vaccination which is 
aspired. Naturally the tendency to tolerate risk is higher with therapeutic vaccines 
than with prophylactic immunizations. 
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Figure 1. Schematic representation of methods to enable or facilitate TCI: (A) transfollicular 
delivery, (B) mechanical dermabrasion, (C) jet injection of liquids or powders, (D) microneedles 
(Images are not drawn to scale) 
 
For example mechanical abrasion of the SC across a large area may be 
acceptable to improve the permeability of an HIV vaccine. In the DermaVir patch 
plasmid DNA encoding for 15 HIV antigens is complexed with mannosylated 
positively charged polyethylene imine to form particles with sizes of 80–400 nm 
[23]. Mannosylation in this case facilitates the uptake of the particles by APCs. The 
patch is applied onto skin sites (2–8 areas 80 cm2 each on the back and the 
thighs) which are previously being abraded with a DermaPrep medical sponge 
(Fig. 1B) [24, 25]. In phase II clinical trials the patch was applied to HIV infected 
individuals on combination antiretroviral therapy (cART) [24, 25]. The treatment 
was well tolerated also in a dose escalation study; mostly side effects were limited 
to mild local irritation [24, 25]. The vaccination increased CD-8+ cell counts and 
may enable intermission of cART [24]. 
Devices such as jet-injectors (Fig. 1C) or gene guns may relatively easily be 
compatible with particle based vaccine formulations. The principle relies on the 
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generation of a jet of liquid or powder formulation which is propelled into the skin 
with great force. Dry formulations have considerable stability advantages. 
Depending on volume and injection depth a small amount of pain or bleeding and 
a relatively strong local inflammation may occur [26]. Immunogenicity is reported 
to be higher or equal to classic vaccine application [26, 27]. The history of using 
jet-injectors for vaccination goes back to the 1950s [28]. Problems with cases of 
hepatitis B which were transmitted person-to-person by multi-dose injectors were 
overcome by next generation devices which may either be prefilled for single use 
or come with exchangeable cartridges [29]. 
As a third technology with great potential to facilitate the absorption of NPs 
microneedles (Fig. 1D), either solid, hollow, or biodegradable, should be 
mentioned. They can be used for pretreatment (e.g., Derma Roller) or as a leave 
on patch which also delivers the formulation. Although not needle-free they reduce 
sharps associated issues. In contrast to intradermal injections (including the 
prefilled syringe system BD soluvia which is approved in Europe for influenza 
vaccination) microneedles only reach the epidermis, stay above the dermal nerve 
endings and avoid pain. The particles can indeed be integrated in the microneedle 
arrays. DeMuth et al. constructed a system made from biodegradable antigen 
loaded MPs [30]. MPs made of poly(lactide-co-glycolide) (PLGA) were embedded 
in water soluble poly(acrylic acid) (PAA) which actually forms the microneedles 
[30]. Upon insertion into the skin, PAA dissolves; the microneedles themselves 
disintegrate and leave a depot of MPs providing controlled release of the antigen 
[30]. This design may enable separate delivery of a fast (from the matrix) and a 
slowly available dose (from the MPs, in mice MP-associated fluorescence was 
demonstrated up to 10 d after microneedle insertion at the site of injection) [30]. 
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Likewise the system could be advanced to deliver initial and booster doses of the 
vaccine in a single application. 
1.1.4. Intrinsic Adjuvant Effect— Influence of Particle Properties 
While for most applications NPs should be inert, that means that complement 
activation is not desirable, an immunostimulatory effect of the nano-formulation 
may be a benefit for vaccination purposes. Various properties such as size, 
surface charge and material properties play a vital role in shaping an immune 
response. A wide variety of particulate systems, including liposomes, virosomes, 
nanocomplexes and polymer based carriers are being investigated, all showing a 
different immunological outcome. For example, a particle based vaccine 
formulation may be capable of provoking a strong humoral response but fail to 
generate cellular responses. This might be due to different particle properties.  
It is widely accepted that particle based vaccine delivery systems are more 
immunogenic than soluble antigen as particulate system mimic the size and 
structure of a pathogen. Among others this is due to the enhanced uptake by 
APCs. Carrier size also plays an important role in determining the type of 
response induced [31]. Recently, Mottram et al. showed that small differences in 
particle size (20–200 nm) influence the cytokine balance after a single 
immunization, showing that particle size in the range of 40–49 nm induces type 1 
(cellular) responses and larger particles with 93–123 nm inducing type 2 (humoral) 
responses [32]. These findings are especially noteworthy while considering 
strategies of immunization against viruses where cellular responses are required.  
Surface charge of the particles is another vital property which not only determines 
the stability of particles but plays an important role in contributing the immuno-
regulatory effect of the particulate systems. With respect to TCI, Rancan et al. 
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showed that positively charged particulate systems seem to be taken up better by 
LCs due to electrostatic interactions with cell membrane eventually favoring their 
internalization [33]. Moreover, Ma et al. showed even the appropriate surface 
charge density is crucial to have an effective and efficacious immune-regulatory 
effect [34]. 
Finally, particle material may influence immunogenicity. The main function of a 
material is to stabilize the antigen by protecting it from the surrounding biological 
conditions, to slow down the clearance of antigens and to enhance delivery to 
APCs with design constraints such as biodegradability and biocompatibility. One 
strategy is to use materials extracted from microbial (e.g., total polar lipid extract 
from archae bacteria, or poly-γ-glutamic acid [35, 36] to formulate particulate 
carriers. Interestingly, the materials themselves do not show adjuvant properties 
when delivered as solution but when formulated as particulate carrier they 
upregulated cytokine responses and MHC molecules, suggesting that particulate 
formation is necessary for the interaction between materials and certain surface 
molecule on APCs [35, 36]. 
1.1.5. Coupling of Nanoparticles with Adjuvants 
Adjuvants are commonly added to vaccine formulations to enhance 
immunogenicity of poorly immunogenic antigens such as subunit vaccines or to 
shape the type of immune response, e.g., to increase cellular responses. For the 
same reasons particulate vaccine formulations may be combined with adjuvants. A 
variety of adjuvants with different mode of actions are being used in clinical 
testing, marketed formulations as well as in research settings. An important 
consideration is the risk of side effects by adjuvants. This is especially true for 
prophylactic vaccines which are given to healthy people and therefore have to 
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fulfill the strongest safety criteria. For example cholera toxin and E. coli heat labile 
toxine (LT) are both very effective adjuvants for TCI and are very effective in 
humans [37].  
 
 
Figure 2. Combinations of antigen and adjuvant in a particulate carrier: (A) adjuvants are co-
administered with the encapsulated antigen, (B) antigen and adjuvant are encapsulated in separate 
particles, (C) antigen and adjuvant are co-encapsulated in same particle, (D) the particle surface is 
decorated with the antigen and/or the adjuvant by physical or chemical association. 
 
Nonetheless considering the application of LT as patch against travelers’ diarrhea 
even the appearance of skin rashes and discoloration at the patch site may lead to 
the termination in a late clinical phase. At present, the choice of adjuvant is a 
compromise between necessity for adjuvanticity and minimal level of side effects 
[38]. Nevertheless, combination of adjuvant, antigen and particulate carrier may 
reduce the dose of antigen as well as adjuvant required in the formulation and 
consequently minimize the risk of side effects of novel adjuvant candidates for 
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prophylactic vaccines [39, 40]. Adjuvants may either be (1) simply co-administered 
with encapsulated antigen, (2) encapsulated in separate particles or (3) co-
encapsulated with the antigen in the same particle. Alternatively the particle 
surface may be decorated with the adjuvant by physical or chemical association 
(Fig. 2). Recently, Bershteyn et al. showed that co-delivery of antigen with an 
adjuvant decorated on the surface of a particle generates humoral as well as 
cellular immune responses at ultra-low doses (at nanogram levels) of antigen and 
adjuvant [41]. In the same study, the authors have shown that co-loading of 
antigen and adjuvant in the same particle after a single immunization was 
significantly advantageous compared with antigen and adjuvant delivered on 
separate particles. But this advantage was lost after a boost immunization, 
suggesting that after boosting it does no longer matter whether antigen and 
adjuvant were on the same or separate particles. However, conflicting results exist 
in literature, whether it is beneficial to co-encapsulate adjuvant and antigen in the 
same particles or admix the adjuvant just prior to immunization (either in solution 
or separately encapsulated) in order to generate long lasting immune responses 
[42, 43]. 
Future studies also need to clarify which type of association between adjuvant and 
particle should be preferred. Conceivably this may depend on the type of adjuvant 
used. For example, an adjuvant which has receptors expressed on the surface of 
APCs (e.g., some sugars such as mannose) will probably benefit from being 
displayed on the particle surface. In contrast, encapsulation of intracellularly 
processed adjuvants will possibly generate a more robust immune response due 
to enhanced uptake by APCs and intracellular delivery compared with 
administration as solution [44]. Overall, combining adjuvant and antigen in 
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particulate carriers either by (co-)encapsulation or admixing is an attractive 
approach to improve the efficacy of vaccines and reduce the cost of vaccination. 
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1.2. Aim of the thesis 
From the introduction section of the thesis and literature survey, it can be easily 
concluded that transcutaneous vaccination promises superior immunogenicity in 
comparison to intra-muscular injection However, many of the current strategies for 
transcutaneous vaccination (e.g. micro-needles, Gene gun, PowderJect, skin 
abrasion), reduce the protective stratum corneum barrier in order to facilitate the 
absorption of the vaccine, making them suboptimal for certain applications, such 
as mass vaccination campaigns in countries having critical hygienic conditions.  
In contrast, transfollicular vaccination aims to reach the peri-follicular antigen 
presenting cells without impairing the SC barrier. Nonetheless, transfollicular 
vaccination is usually performed after pre-treating the skin area by plucking the 
hairs, waxing, or cyanoacrylate (superglue) stripping. 
Thus, the aim of this thesis was to evaluate the potential of transfollicular 
vaccination using nanoparticles without applying SC barrier-reducing measures. 
The following strategy was used to achieve this aim. Firstly, proof of concept 
studies were conducted to answer whether immune responses could be generated 
via the transfollicular route without skin pre-treatment, with the help of an adoptive 
transfer mouse model using ovalbumin as model antigen and encapsulating it 
inside polymeric nanoparticles (chapter 4). Extensive characterization of immune 
responses triggered by transfollicular vaccination using ovalbumin-loaded 
nanoparticles without skin pre-treatment was then carried out using normal 
C57BL/6 mice (chapter 5). Moreover, side-by-side comparisons of different 
formulations on tape stripped and intact skin were conducted to determine the 
necessity of different components of nano-formulations to generate immune 
responses via this pathway (chapter 5). Furthermore, a new nanoparticulate 
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delivery system was fabricated to apply learning from the above mentioned studies 
and to formulate a better delivery system (alleviating observed shortcomings of 
polymeric nanoparticles) for generation of better immune responses via the 
transfollicular route as well as via other routes of vaccination. 
  
The work in this thesis has been divided into the following chapters, under which 
the above points are explored in more detail: 
 
Chapter 2: Non-invasive delivery of nanoparticles via hair follicles 
Chapter 3: Efficient nanoparticle-mediated needle-free transcutaneous vaccination 
via hair follicles requires adjuvantation    
Chapter 4: Inverse micellar sugar glass nanoparticles as delivery system: adjuvant 
co-encapsulation and administration route have a major impact on 
immunization outcome 
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2. Non-invasive delivery of nanoparticles via hair follicles 
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2.1 Abstract 
Transfollicular vaccination aims to reach the peri-follicular antigen presenting cells 
without impairing the stratum corneum (SC) barrier. This would be an optimal 
vaccination strategy under critical hygienic conditions. Nanoparticles (NPs) are the 
ideal vehicles for transfollicular delivery of vaccines as they are able to (i) 
penetrate deeper into the hair follicles than molecules in solution, (ii) can help to 
stabilize protein based antigen and (iii) improve and modulate the immune 
response. 
This study investigates the potential of transfollicular delivery of polymeric NPs 
using ovalbumin (OVA) as a model antigen. The NPs were prepared by a double 
emulsion method from pharmaceutically well characterized biocompatible and 
biodegradable polymers poly(lactide-co-glycolide) (PLGA) or chitosan-coated 
PLGA (Chit-PLGA) using polyvinyl alcohol as stabilizer. The NP formulations are 
available as freeze dried product which can be re-constituted with water or cell 
culture medium before use to yield any desired OVA/NP concentration. OVA was 
protected from cleavage or aggregation inside the NPs and retained its biological 
activity to 74% (PLGA) and 64% (Chit-PLGA). Thus, when applying a typical dose 
of 8.5 µl NP formulation per cm² (50 mg NPs/ml, 54.3 ± 0.047 and 66.5 ± 0.044 µg 
OVA/mg NPs for PLGA and Chit-PLGA NPs respectively) an effective dose of 
17 µg/cm² (PLGA) or 18 µg/cm² (Chit-PLGA) of active OVA is administered. In a 
cell culture assay encapsulated OVA stimulated the proliferation of CD4+ (PLGA 
and Chit-PLGA) and CD8+T-cells (only Chit-PLGA) to a larger extent than OVA in 
solution. Both NP formulations improved the delivery efficiency of OVA into the 
hair follicles on excised pig ears by a factor of 2-3 compared to OVA solution. This 
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delivery efficiency could further be increased by increasing the number of NPs 
applied per skin area by a factor of ≈2-2.4.  
Consequently formulation of OVA into PLGA and Chit-PLGA NPs may offer to 
reduce the dose which needs to be applied for transfollicular immunization. 
 
2.2. Introduction 
Transcutaneous immunization (TCI) refers to the needle-free application of 
vaccines across the skin [45]. Major benefits include the possibility of self-
administration, improved patient compliance, no requirement of “sharps” waste 
removal, and reduced storage and transport issues. The skin is a superior organ 
for eliciting an immune response compared to the muscle due to the abundance of 
professional antigen presenting cells (APCs) such as dendritic cells (DCs) and 
Langerhans cells (LCs) in different layers of the skin [8, 46]. In addition, TCI can 
generate both a humoral as well as a cellular response at the site of administration 
and also at distant mucosal sites [22]. Hence, TCI may allow reducing the antigen 
dose, as well as eliciting an improved immune response in persons with a disease- 
or age-compromised immune system [47].  
The major challenge for TCI is to enhance the transport of antigens across the 
stratum corneum (SC) barrier. To this end often barrier disrupting measures are 
applied, such as chemical permeation enhancers, abrasion, electroporation, micro-
needles, PowderJect, gene gun, etc. In contrast, transfollicular vaccination aims to 
deliver antigens to the abundant perifollicular APCs [14, 48]. Any additional barrier 
disrupting measures should be expendable as the SC only extents into the upper 
third of the follicle. Solid NPs are the ideal vehicles for transfollicular delivery as 
they accumulate in hair follicles and skin folds and penetrate deeper into hair 
follicles than molecules in solution [19]. Transfollicular delivery has been widely 
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investigated for DNA vaccines, and lately also for non-nucleotide based antigens 
such as a seasonal flu vaccine as well as nanoparticle (NP) based formulations  
Nonetheless, transfollicular vaccination is usually performed after pretreating the 
skin area by plucking the hairs, waxing, or cyanoacrylate (superglue) stripping. 
This pretreatment induces the hair cycle into anagen (proliferation) state and 
markedly increases the transfection efficiency of follicular keratinocytes [15, 49]. 
The pretreatment is therefore helpful for DNA vaccines, however, it may be 
expendable for protein or peptide based antigens. At the same time the SC is (at 
least partially) removed so that it is not clear to which extent the antigen 
penetrates via the hair follicles or across the permeabilized SC. This is especially 
critical as the reduced barrier increases the risk of pathogen entry which is of 
particular importance for transfolliclular vaccination in (i) countries with critical 
hygienic conditions, and (ii) immuno-compromised individuals, such as elderly 
people with poor wound healing and young children.  
This study investigates the potential of transfollicular delivery of ovalbumin (OVA) 
using polymeric nanoparticles (NPs) without compromising the SC barrier by any 
pretreatment for the purpose of non-invasive TCI. NPs were prepared by a double 
emulsion method from poly(lactide-co-glycolide) (PLGA) or chitosan-coated PLGA 
(Chit-PLGA) and polyvinyl alcohol (PVA) as stabilizer. These are biocompatible 
and biodegradable polymers which are widely used for biomedical applications. 
The NPs were characterized physico-chemically in terms of size, surface charge, 
OVA encapsulation/loading and morphology. The integrity and biological activity of 
the encapsulated OVA was monitored by SDS page, in vitro proliferation of OVA-
specific lymphocytes, and ELISA. The follicular delivery efficiency was measured 
in intact pig skin based on the differential stripping technique and compared to 
OVA solution [19, 50]. An adoptive transfer experiment was performed as a proof 
Non-invasive delivery of nanoparticles via hair follicles  
 
22 
 
of concept study, to analyze the usefulness of the non-invasive transfollicular 
immunization route.  
To our knowledge this is the first study to evaluate the potential of transfollicular 
vaccination using NPs without applying SC barrier reducing measures. 
 
 
2.3. Materials and methods 
2.3.1. Material 
EndoGrade® Ovalbumin (OVA) was obtained from Hyglos GmbH (Bernried, 
Germany); poly(d,l-lactide-co-glycolide) (PLGA) (Resomer RG 50:50 H; inherent 
viscosity 0.31 dL/g) was kindly provided by Boehringer Ingelheim (Boehringer 
Ingelheim GmbH & Co. KG, Ingelheim, Germany); polyvinyl alcohol (PVA) 
Mowiol® 4-88 was obtained from Kuraray Specialties Europe GmbH (Frankfurt, 
Germany); ultrapure chitosan chloride salt (Protasan® UP CL113) was purchased 
from FMC BioPolymer AS (Oslo, Norway); trehalose was obtained from Sigma-
Aldrich (St. Louis, MO, USA); fluorescein isothiocyanate conjugated ovalbumin 
(FITC-OVA) was obtained from Invitrogen (Molecular Probes Inc., Germany). 
Superglue was kindly provided by Uhu GmbH & Co.KG, (Bühl, Germany). Tesa 
film was obtained from TESA SE, Hamburg, Germany. The OVA specific ELISA kit 
was purchased from USCN life science Inc. (Hölzel Diganostik, Germany). All 
other solvents and chemicals used were of the highest grade commercially 
available. Deionized water (Milli Q Plus system, Millipore, Bedford, MA, USA) was 
used throughout the investigation. 
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2.3.2. Pig ear skin 
Ears from freshly slaughtered pigs were removed before scalding. The ears were 
washed with water, blotted dry and the hairs were shortened with scissors. The 
ears were stored at 4-8 °C for a maximum period of 3 days. 
2.3.3. Mice 
Female BALB/c (H-2d) or C57BL/6 (H-2b) mice at the age 6-8 weeks were 
purchased from Harlan (Germany). OVA-TCR transgenic mice OT-I (C57BL/6-
Tg(TcraTcrb)1100Mjb/J) and OT-II (C57BL/6-Tg(TcraTcrb)425Cbn) were bred at 
the animal facilities of Helmholtz Centre for Infection Research under specific 
pathogen-free conditions. 
2.3.4. Nanoparticles preparation  
PLGA NPs were prepared by a modified double emulsion method [51]. Briefly, 
50 mg of PLGA were dissolved in 2 ml of ethyl acetate at room temperature. Then 
400 μl of (1.875% wt/V) OVA solution in water was added to form a primary water-
in-oil (w/o) emulsion. After sonicating at 20 % amplitude (A) for 15 s, 4 ml of 2% 
(wt/V) PVA solution was added to the primary emulsion and again sonicated at 
20 A for 20 s. Water was added drop-wise to the resulting w/o/w emulsion under 
constant stirring to allow diffusion and evaporation of the organic solvent. The 
particles were collected by centrifugation at 10,000 g for 15 min, washed once with 
distilled water to remove excess surfactant and free drug and freeze dried using 
trehalose (0.2% wt/V) as cryoprotectant. 
Chit-PLGA NPs were prepared in a similar manner as described above with the 
difference that Protasan® UP CL113 (0.2% wt/V) was added to the PVA solution.  
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FITC labeled OVA loaded NPs and FITC labeled blank NPs were prepared by 
replacing OVA or the PLGA polymer with their fluorescent counterparts, 
respectively. 
2.3.5. Nanoparticle characterization 
Size and ζ-potential of the NPs were analyzed by photon correlation spectroscopy 
(PCS) using a Nano-ZS (Malvern Instruments, Malvern, UK). The morphology of 
the NPs was characterized using scanning electron microscopy (SEM) (JSM 
7001F Field Emission SEM (Jeol, Japan)) and atomic force microscopy (AFM) 
(Multimode V (Veeco, USA)). For SEM, prior to scanning, NPs were sputtered with 
gold (layer thickness approximately 10 nm). The accelerating voltage was 10 kV 
with a focal distance of 10 mm. For AFM imaging, NPs were scanned using 
tapping mode and scan rates of 0.6 Hz. A standard non-contact mode cantilever 
was used for imaging (OMCL-AC160TS, Olympus, Essex, Great Britain). 
The entrapment efficiency (% EE = wt OVA encapsulated/wt OVA added initially) 
and loading efficiency (% L = wt OVA encapsulated/wt polymer) of OVA in PLGA 
and Chit-PLGA NPs were determined using a QuantiPro bicinchoninic acid (BCA) 
assay (Pierce, Rockford, IL, USA) according to the manufacturer’s instructions for 
96 micro-well plates. Briefly, 5 mg of the lyophilized particles were hydrolyzed in 
0.1 N NaOH for 6 h and then neutralized with 0.1 N HCl [51]. Blank NPs were 
used as a control.  
2.3.6. Integrity and Activity of OVA 
The integrity of OVA was determined by SDS PAGE analysis. Briefly, OVA was 
extracted from freeze-fried NPs under alkaline conditions (0.1 N NaOH). The total 
amount of protein was quantified using a QuantiPro BCA assay. A dose of 1 µg of 
OVA was loaded onto a 12% (wt/V) polyacrylamide gel under reducing conditions 
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[52]. Detection of protein was performed by staining with colloidal Coomassie blue 
(Fermentas, St. Leonrot, Germany). 
To determine the activity of OVA encapsulated in NPs 1 ml of each NP dispersion 
(1 mg/ml) was incubated for 24 h in phosphate buffer (pH 5.5) at 32 °C under 
continuous stirring at 100 rpm. The dispersion was centrifuged for 20 min at 
24,000 g and the total amount of protein in the supernatant was quantified using a 
QuantiPro BCA assay. Subsequently, the active OVA fraction was quantified using 
an ELISA assay which was performed according to the instructions provided by 
the manufacturer. The ELISA was calibrated using standards provided by the 
manufacturer in the range of 0.156 – 10 ng/ml (lower limit of detection, LLOD = 
0.053 ng/ml). Supernatant obtained from blank NPs were used as negative 
control. 
2.3.7. DC activation and stimulation: Preparation and flow cytometric 
analysis of murine dendritic cells 
Bone marrow-derived primary dendritic cells (conventional DCs) from C57BL/6 
mice were generated by flushing femur and tibia of mice with media. Erythrocytes 
were lysed by adding ACK buffer (0.15 M NH4Cl, 1.0 M KHCO3, 0.1 mM EDTA, pH 
7.2). Cells were washed and incubated on cell culture dishes for up to 2 h. Then 
non-adherent DC precursors in the supernatant were transferred to 12-well plates 
(2 x 106/well) and differentiated for 5 days in media supplemented with 50 ng/ml 
GM-CSF. On day 5, DCs were co-incubated with PLGA OVA [10 µg/ml], Chit-
PLGA OVA and different controls, such as PLGA alone for 24 h at 37°C. Control 
cells were treated with OVA LPS free [10 µg/ml] and OVA co-administered with 
LPS derived from Salmonella enterica Serovar Typhimurium (Invivogene) at a final 
concentration of 1 µg/ml. For flow cytometry, cells were pre-blocked using anti-
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mouse CD16/32 antibody for 15 min. Then, DCs were stained with several 
differentiation and maturation markers conjugated with different fluorochromes, 
such as CD40 (HM40-3), CD54 (YN1/1.7.4), CD80 (16-10A1), CD86 (GL1), MHC-
II M5/114.15.2), and MHC-I (34-1-2S) antibodies (eBioscience, USA). The FACS 
analysis of 20,000 events was performed using a LSR-II and the FACSDiva 
software (BD Bioscience, USA), gating on CD11c positive cells. Results are 
expressed as histograms and correspond to one representative experiment out of 
three independent tests. 
2.3.8. Measurement of cellular proliferation of antigen specific murine CD4+ 
and CD8+ T cells  
Differentiated murine DCs were incubated with 10 µg/ml of LPS-free OVA 
(EndoGrade® OVAlbumin, #321001, Hyglos, Germany), PLGA or PLGA-OVA and 
Chitosan-PLGA or Chitosan-PLGA-OVA. After 24h CD8+ T cells derived from 
spleens of OT-I mice, which have a transgenic T cell receptor specific for the OVA 
immune-dominant peptide (aa 257-264, SIINFEKL) presented in the context of the 
MHC class I H-2Kb, or CD4+ T cells derived from spleen of OT-II mice expressing 
the TCR specific for OVA (aa 323–339, ISQAVHAAHAEINEAGR) presented in the 
MHC class II molecule I-Ab were isolated. Afterwards, the spleen cells were 
stained with 10 µM carboxy fluorescein succinimidyl ester (CFSE; Molecular 
Probes, USA) in PBS for 5 min and co-cultured with antigen stimulated murine 
DCs for 4 days. The loss of CFSE+ labelling of CD8+ and CD4+ T cells in 
response to stimulation with PLGA-OVA or Chitosan-PLGA-OVA were determined 
by flow cytometry on a BD LSR-II and analysed using the FACSDiva software. 
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2.3.9. Adoptive transfer model of TCR transgenic CD4 T cells to characterize 
OVA specific proliferation 
Naïve non-activated CD4 T-cells (CD4+ CD62Lhi CD44lo CD25-) were isolated from 
pooled lymph nodes and spleens of OTII x Thy1.1 mice by FACS with an ARIA II 
sorter (purity ≥98%). These cells express an OVA-peptide AA323-339 specific T 
cell receptor (TCR) and the congenic marker Thy1.1 (CD90.1, while wild type mice 
express Thy1.2 (CD90.2)). The congenic marker, which slightly differs in structure 
but not in function, allows the identification of the transferred cells ex vivo by non-
cross-reactive monoclonal antibodies. The sorted cells were labeled with CFSE to 
track their proliferation later on.  
Immunization was carried on the flank part of the mice. Flank part of mice were 
shaved (under anesthetic) at least 2 d before immunization. Shaved areas were 
carefully inspected for cuts or skin irritation in which case these mice were 
excluded from the experiment. A day prior to immunization the CFSE labeled cells 
were transferred to OVA naïve C57BL/6 mice by tail vein injection (1.5 x 106 per 
mouse). On the day of immunization, the mice were immunized either i.m. or via 
the transfollicular route.  
The animals were assorted to the following treatment groups (4 animals per 
group): (1) negative control, received Chit-PLGA + 5 µg c-di-AMP as adjuvant 
dispersed in physiological buffer via i.m. injection; (2) positive control, received 
200 µg / 50 µl LPS-free OVA dissolved in physiological buffer via i.m. injection; (3) 
received 200 µg LPS-free OVA in Chit-PLGA NPs + 5 µg c-di-AMP as adjuvant via 
transfollicular application. After another 4 days the animals were sacrificed and 
spleens and draining lymph nodes (illiac and axillary LNs pooled) were isolated 
separately for each animal. Cells were stained for live/dead, CD3+, CD4+ and 
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Thy1.1+ and analyzed with a LSRII flow cytometer. Cells were gated for viability, 
CD3+ CD4+ Thy1.1+ and the proliferation (CFSE dilution) was analyzed. 
2.3.10. Evaluation of follicular uptake on excised pig ears 
Incubation sites of 1.767 cm² were marked on the outer auricle of the pig ears with 
a permanent marker. A dose of 15 µl of either an aqueous solution of FITC-OVA, 
an aqueous dispersion of FITC-OVA in PLGA NPs, or FITC-OVA in Chit-PLGA 
NPs (8.5 µg OVA/cm², 0.42 and 0.36 mg NPs/cm² for PLGA NPs and Chit-PLGA 
NPs, respectively) were applied and massaged manually with a gloved forefinger 
for 3 min. The ears were incubated for 1 h at 32°C under non-occlusive conditions. 
2.3.11. Microscopical evaluation 
Cross-sections of 12 µm thickness were performed on a cryomicrotome (Cryostat 
Type MEV, Slee, Mainz, Germany). The biopsy was placed in a vertical direction 
relative to the blade to prevent the spreading of NPs from the skin surface to 
deeper skin layers. The sections were collected on objective slides, embedded in 
FluorSave™ embedding medium (Calbiochem®, USA) and sealed with a cover 
slip.  
For the top view image, a skin biopsy was mounted on an objective slide with 
distance holders and sealed with a cover slip, which immediately touched the skin 
as well as the distance holders to prevent any skin movement during the imaging 
process.  
Cyanoacrylate biopsies were obtained as described below and fixed on an 
objective slide.  
All samples were imaged under the confocal microscope (Zeiss LSM 510 META 
system, Carl Zeiss, Jena, Germany). An Argon laser at 458 nm was used to excite 
the fluorescence signal. As objective a water immersion lens 25X was used. The 
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high auto fluorescence of the skin was excluded by choosing appropriate filters 
and gain settings. In addition, for the cross-sections and cyanoacrylate biopsies 
transmission light images were superimposed with the fluorescence images. For 
top-view and cyanoacrylate biopsy images optical stacks (z-stacks) were 
performed. Image processing was performed using Volocity® 3D Imaging Analysis 
Software (Perkin Elmer Inc. USA). 
2.3.12. Quantification of follicular uptake: Influence of encapsulating OVA 
into particles  
After the incubation the skin surface was cleaned from remaining formulation by 
removing 10 tape strips (Tesa kristallklar, Tesa SE, Germany). A roller was used 
to enhance the contact between tape strip and skin surface [53]. Subsequently, 2 
cyanoacrylate biopsies were performed to collect the amount of OVA penetrated 
into the hair follicles. The cyanoacrylate biopsies were extracted in 
acetonitrile:0.1 N NaOH (70:30) for 3 h on a horizontal shaker and the 
fluorescence intensity of all samples was measured using a Tecan platereader 
(Excitation 490 nm, Emission 525 nm). The amount of FITC-OVA extracted from 
the cyanoacrylate biopsies was calculated with the help of standards prepared 
from FITC-OVA / FITC-OVA in PLGA NPs / FITC-OVA in Chit-PLGA NPs 
dissolved in acetonitrile : 0.1 N NaOH (70:30) in the range of 0.1-10 µg/ml. The 
results for the NPs were expressed relatively to FITC-OVA solution.  
Blank samples were taken from an incubation site of the same pig ear, double 
distilled water was applied instead of NPs. The blank values were subtracted from 
the fluorescence intensity of the samples. 
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2.3.13. Quantification of follicular uptake: Influence of particle concentration 
Follicular uptake was quantified using particle concentrations of 0.22/0.42/0.85 mg 
NPs/cm². Briefly, 15 µl of each NP dispersion at a concentration of 25/50/100 mg 
NPs/ml were applied to an area of 1.767 cm² and processed exactly as described 
above. The NPs used in these experiments were prepared using FITC-PLGA to 
enable detection and did not contain any OVA. FITC-labeling of PLGA was 
performed as described in [54]. Standards were prepared from blank FITC-PLGA 
or Chit-FITC-PLGA NPS in the range of 5-380 µg/ml dispersed in acetonitrile:0.1 N 
NaOH (70:30). Blank samples were taken from an incubation site of the same pig 
ear, double distilled water was applied instead of NPs. The blank values were 
subtracted from the fluorescence intensity of the samples. 
2.3.14. Statistical analysis 
Statistical analysis was performed by a one-way ANOVA. A p value of ≤ 0.05 was 
considered significant. 
 
2.4. Results 
2.4.1. Characterization of Nanoparticles 
The SEM and AFM images in Fig.1 show smooth, spherical particles. The 
characteristics of the NPs are summarized in Table 1. The mean size of OVA 
loaded PLGA and Chit-PLGA NPs was ca. 170 nm and 180 nm, respectively, with 
a monodisperse size distribution (PDI < 0.2). 
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Table 1 
Physico-chemical characterization of the optimized PLGA and Chit-PLGA NPs 
Nanoparticle Size (nm) PDI Z.P. (mV) % EE % L %A 
Blank PLGA 
162.8 ± 
1.66 
0.056 ± 
0.005 
-31.5 ± 
1.03 
- -  
OVA loaded PLGA 
168.5 ± 
1.45 
0.063 ± 
0.008 
-24.8 ± 
0.89 
27.61 ± 
1.03 
5.43 ± 
0.19 
73.59 ± 
2.91 
Blank Chit-PLGA 
171.5 ± 
1.36 
0.123 ± 
0.012 
24.1 ± 
0.78 
- -  
OVA loaded Chit-
PLGA 
183.6 ± 
2.71 
0.171 ± 
0.012 
20.2 ± 
1.05 
36.54 ± 
1.08 
6.65 ± 
0.18 
63.57 ± 
2.68 
Values represent mean ± standard error of the mean (SEM) of n = 6 independently prepared 
batches, except for %A where n = 3. Z.P. zeta potential, %EE encapsulation efficiency (wt OVA 
encapsulated/wt OVA added initially), %L loading (wt OVA encapsulated/wt polymer), %A activity 
(wt OVA active/OVA encapsulated) 
 
 
Figure 1. Top: (a) & (b) SEM and AFM images of OVA loaded PLGA NPs; bottom: (c) & (d) SEM 
and AFM images of OVA loaded Chit-PLGA NPs 
PLGA NPs have a negative surface charge whereas Chit-PLGA NPs have a 
positive surface charge. Antigen incorporation into PLGA and Chit-PLGA NPs 
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slightly increased the particle size and reduced the overall surface charge 
compared to blank NPs. For both particle types similar %EE of 27.61 ± 2.52% and 
36.54 ± 2.44% and %L of 5.43 ± 0.47% and 6.65 ± 0.44% were obtained (for 
PLGA and Chit-PLGA NPs respectively). 
2.4.2. Integrity and Activity of OVA 
To investigate the formation of fragments or aggregates of OVA during NP 
preparation, an SDS PAGE was performed. Weak differences in the migration 
pattern of OVA extracted from NPs compared to control (OVA in aqueous solution) 
were observed as shown in Fig. 2. While no fragments were obtained, low 
amounts of higher molecular weight adducts, probably dimers and trimers (ca. 95 
and 135 kDa), were observed in the case of OVA extracted from NPs. Lanes 3 
and 5 (blank NPs) show that no interference from the NP formulations is to be 
expected. 
 
Figure 2. Integrity of OVA extracted from NPs by 0.1 N NaOH and analyzed by SDS PAGE, Lane 
1: MW standards, Lane 2: OVA control, Lane 3: Blank PLGA, Lane 4: OVA extracted from PLGA 
NPs, Lane 5: Blank Chit-PLGA, Lane 6: OVA extracted from Chit-PLGA NPs 
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In addition, ELISA was performed using the OVA which had been extracted from 
the NPs. By relating the result to the total amount of protein in the sample the 
activity of the encapsulated OVA was determined as 74% and 64% in PLGA and 
Chit-PLGA NPs, respectively.  
2.4.3. Activation of dendritic cells 
We analyzed the effect of PLGA-OVA and Chit-PLGA-OVA on the activation and 
maturation of bone marrow-derived murine DCs. Both, PLGA-OVA and Chit-
PLGA-OVA were able to promote an efficient activation and maturation of DCs in 
vitro when used at a final OVA concentration of 10 µg/ml. Changes in the 
activation markers (% of CD11c+ DCs indicates the number of activated DCs; MFI 
indicates the expression level of a certain marker per cell) were modest but except 
for CD54 an increase compared to negative control was detected for all NP groups 
as well as for OVA alone (Fig. 3). Interestingly, no significant differences in the 
expression levels of activation markers per cell have been observed comparing 
values of DCs stimulated with OVA alone with those of DCs incubated in the 
presence of any NP formulation (Fig. 3). In general incubation of DCs in the 
presence of OVA alone and in combination with LPS stimulated similar changes in 
activation markers except for CD40 and CD80 where the addition of LPS 
increased the marker expression per cell (Fig. 3).  
However, we next evaluated the capacity of APCs loaded with antigen in presence 
of PLGA-OVA and Chit-PLGA-OVA to stimulate the proliferation of antigen-specific 
CD8+ and CD4+ T cells. DCs stimulated with OVA loaded Chit-PLGA NPs were 
able to induce a strong antigen-specific proliferation of CD8+ T cells (67.5%) from 
OT-I mice, as shown by the loss of CFSE+ stained cells (Fig. 4, left column).  
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Furthermore, theses DCs were also able to stimulate the proliferation of CD4+ T 
cells (95.6%) derived from OT-II mice (Fig. 4, right column). Nevertheless, weaker 
T cell proliferation was also observed when DCs were stimulated with OVA LPS-
free alone (21 and 68%, respectively). DCs stimulated with OVA loaded PLGA 
NPs were also able to stimulate the proliferation of OT-I and OT-II cells although to 
a lesser extend compared with OVA alone and the OVA loaded Chit-PLGA NPs 
(10 and 95.1%, respectively). OVA free NPs promote only very marginal DC 
activation/ T-cell proliferation if any at all (Fig. 4). Interestingly, LPS induced only 
week CD4+ T cell proliferation compared to OVA and PLGA-OVA and Chit-PLGA-
OVA (Fig. 4). 
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Figure 3. Expression of activation marker by murine DCs after stimulation with PLGA-OVA and 
Chit-PLGA-OVA. The expression of surface markers on CD11c
+
-gated bone marrow-derived 
murine DCs following stimulation with OVA LPS free [10 µg/ml], PLGA, PLGA-OVA [10 µg/ml], 
Chit-PLGA and Chit-PLGA-OVA [10 µg/ml], respectively, was investigated by flow cytometry. After 
24 h of incubation DCs were stained with Abs specific for CD40, CD54, CD80, CD86, MHC-I and 
MHC-II molecules and analyzed by flow cytometry (BD LSR-II). Results are mean ± SEM of three 
independent experiments and expressed as percentage (a) and mean fluorescence intensity (MFI) 
(b), respectively, of CD11c+ cells.  
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Figure 4. Ova-specific proliferation of OT-I (left panel) and OT-II lymphocytes (right panel) 
stimulated by NP-OVA pulsed DCs. Bone marrow-derived DCs were incubated for 24 h in the 
presence of OVA LPS free [10 µg/ml], PLGA, PLGA-OVA [10 µg/ml], Chit-PLGA and Chit-PLGA-
OVA [10 µg/ml], respectively. Non-stimulated pulsed DCs were used as negative control. Then, the 
loaded DCs were co-cultured with either CFSE labeled naïve CD8
+
 or CD4
+
 T cells derived from 
OT-I and OT-II mice, respectively, for 4 days and further analyzed by flow cytometry. The results 
are representative out of two experiments and are expressed as histograms showing the 
percentage of proliferating OVA-specific T cells of all CD8+ (OT-I) and CD4+ (OT-II) T cells, 
respectively. 
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2.4.4. Adoptive transfer model of TCR transgenic CD4 T cells to characterize 
OVA specific proliferation 
In order to verify the feasibility of transfollicular immunization as alternative 
vaccination strategy, an adoptive transfer model was established. Proliferation of 
adoptively transferred OVA specific CD4 T cells was measured by CFSE dilution 
in the draining lymph nodes and secondary lymphatic organ.  
The number of divided OVA specific CD4 T cells is shown in Fig. 5 (one 
representative animal of 4 animals per group). As expected no proliferation of 
transferred cells isolated from draining lymph nodes have been observed in the 
negative control (Fig. 5a), whereas animals of group 2 (immunized i.m. with OVA 
protein as positive control) showed a strong proliferation (95.9% of the transferred 
cells proliferated, Fig. 5b). Mice immunized by transfollicular application of Chit-
PLGA-OVA co-administered with c-di-AMP as adjuvant showed a comparable 
proliferation potential (96.2%, Fig. 5c).  
Fig. 6 shows the percentage of divided transferred cells for each experimental 
group. The four animals of each group were analyzed separately. While no 
proliferation was observed in the negative control (group 1), full proliferation of the 
transferred cells was observed in animals of the positive control group (group 2) 
and in animals immunized transfollicularly with Chit-PLGA-OVA and c-di-AMP as 
adjuvant (group 3). This experiment demonstrates that the model antigen OVA can 
be delivered via the transfollicular route and that the immunization by this route is 
able to elicit the same proliferation OVA specific CD4+ T cells as the i.m. injection 
of OVA. 
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Figure 5. Animals of group 1 were immunized with empty Chit-PLGA NPs and the adjuvant c-di-
AMP i.m.. As expected no proliferation of transferred cells was observed in this negative control 
(A). Animals of group 2 were immunized i.m. with OVA protein as positive control. More than 95% 
of the transferred cells proliferated after this stimulation (B). The mice of group 3 were immunized 
by transfollicular application of OVA loaded Chit-PLGA NPs and c-di-AMP as adjuvant which led to 
proliferation comparable to the positive control (C). Shown is the proliferation of cells isolated from 
draining lymph nodes of one representative animal per group. 
 
 
 
Figure 6. The percentage of divided transferred cells in the draining lymph nodes (a) and the 
spleen (b) for each experimental group is shown. The four animals of each group were analyzed 
separately. While no proliferation was observed in the negative control (Gr.1), full proliferation of 
the transferred cells was observed in animals of the positive control group (Gr.2) and in animals 
immunized transfollicularly with Chit-PLGA-OVA and c-di-AMP as adjuvant (Gr.3.). This experiment 
demonstrates that the model antigen OVA can be delivered via the transfollicular route and that the 
immunization by this route is able to elicit the same proliferation of OVA specific CD4+ T cells as 
the i.m. injection of OVA. 
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2.4.5. Follicular uptake of Nanoparticles 
Fig. 7 shows representative images illustrating the distribution of fluorescently 
labeled NPs on the skin surface and in the hair follicle after application to excised 
pig ears. From both the cross-section as well as the top-view it is apparent that the 
NPs accumulated in the follicle openings, cover the hair and invade into the 
follicular duct (Fig. 7(a,b)). Fig. 7c shows a cyanoacrylate biopsy of the follicular 
content, which further confirms the presence of NPs inside the hair follicles.  
 
Figure 7. Distribution of fluorescently labeled NPs in hair follicles after application to excised pig 
ears. (LSM 510 Meta, Carl Zeiss GmbH, Jena Germany; excitation wavelength 458 nm)  
(a) Top view onto the skin surface – image reconstituted after optical sectioning (41 individual 
frames of 3 µm thickness): NPs accumulate in the follicle opening. The hair is visible as a negative 
image due to NPs on the hair surface. 
(b) Transversal cryo section (thickness 12 µm); overlay of fluorescence and transmission light 
images: NPs are visible on the skin surface and inside the follicle.  
(c) Cyanoacrylate biopsy – one plane selected from optical sectioning (section thickness 0.5 µm); 
the position of the plane relative to the entire optical stack can be estimated from the height of the 
box; overlay of fluorescence and transmission light images; the skin surface is oriented towards the 
bottom of the image: NPs are visible deep inside the cyanoacrylate biopsy which was performed to 
extract the follicular content. 
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By extracting cyanoacrylate biopsies with organic solvents and quantifying the 
fluorescence in the extract the uptake into the follicles was quantified (Fig. 8). 
Encapsulation of OVA into NPs significantly enhanced follicular uptake of OVA by 
a factor of 2.85 ± 0.6 (FITC-OVA in PLGA NPs) and 2.33 ± 0.52 (FITC-OVA in 
Chit-PLGA NPs) compared to OVA solution (Fig. 8a). Follicular uptake of OVA 
was slightly lower for Chit-PLGA compared to PLGA NPs; however, this difference 
was not significant (Fig. 8a).  
 
Figure 8. (a) Uptake of FITC-labeled OVA encapsulated in NPs relative to FITC-OVA solution A: 
FITC-Ova solution, B: FITC-OVA in PLGA NPs, C: FITC-OVA in Chit-PLGA NP. (applied dose: 
8.5 µg OVA/cm², 0.42 mg NPs/cm²; n = 6, mean ± SEM; * indicates significant differences 
compared to A with p ˂ 0.05) 
(b) Effect of NP concentration on follicular uptake. The results are expressed relatively to the 
lowest NP concentration. (n = 3 except for the highest conc. measured with Chit-PLGA NPs where 
n = 2, mean ± SEM; * indicates significant differences compared to the lowest NP concentration 
with p ˂ 0.05) 
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Furthermore, using FITC-labeled PLGA it turned out that follicular uptake of 
particles is a function of the NP dose/area relation. Thus the uptake can further be 
enhanced by increasing the NP concentration in the formulation (Fig. 8b). 
 
2.5. Discussion 
Transfollicular delivery of antigen by using NPs holds the potential for TCI without 
the need to weaken the protective SC barrier. So far, studies demonstrating 
transfollicular antigen delivery used additional barrier disrupting methods such as 
tape stripping, plucking or intense skin hydration [15, 55, 56]. We hypothesize that 
by encapsulating the antigen into NPs transfollicular vaccination can be optimized 
benefiting from the unique properties of such formulations which should finally 
allow the application without any barrier disrupting measures. Most NPs cannot 
overcome the intact SC except for ultrafine particles (<10 nm, consequently 
suffering from an extremely low loading capacity) and ultra-flexible liposomes [8]. 
However, once the particles are located deep inside the hair follicles the SC is no 
longer an obstacle towards penetration. It has already been demonstrated 
(although only in mice) that 200 nm particles can be taken up by perifollicular 
APCs [55, 56].In fact, transfollicular vaccination by using NPs to encapsulate the 
vaccine antigen imitates the natural route of delivery observed for pollen allergens 
in patients suffering from atopic dermatitis. Pollen grains are micron-sized particles 
which accumulate in the follicle openings and release the allergen after getting into 
contact with sweat [13, 57]. Also, upon depletion LCs quickly re-populate the 
epidermis within a period of 24 h, the primary source for LCs being the hair 
follicles [58, 59]. 
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In this study we prepared polymeric NPs from PLGA and/or chitosan. Both 
polymers are widely used for drug delivery purposes, especially for preparing 
depot formulations with a sustained bioavailability of protein and peptide drugs 
[60-62]. Chitosan and its derivatives are widely used as non-viral vectors for 
nucleotide based drugs as these are easily complexed by the positively charged 
polymer [63, 64]. Both polymers are “generally regarded as safe” (GRAS), 
biocompatible and biodegradable. Chitosan furthermore has mucoadhesive 
properties, facilitates permeation, and has intrinsic adjuvant properties [65, 66]. 
Encapsulation into NPs can help to stabilize protein based antigen, modify the 
release, and improve uptake by APCs [67-69]. At the same time the NP 
preparation process itself threatens protein integrity and bioactivity due to 
exposure to organic solvents, interfacial tension, and high shear forces [70]. 
Liquid/liquid and solid/liquid interfaces occur during all steps of protein 
encapsulation, protein release and storage and may cause conformational 
changes and/or aggregation. Apart from losing therapeutic activity aggregates may 
cause unpredictable side effects and lead to immunogenicity or toxicity [62]. 
During storage these issues may be minimized by freeze-drying. However, upon 
reconstituting the lyophilisate and during drug release degradation of PLGA will 
create an acidic microenvironment which leads to acidic hydrolysis of protein 
antigens [71, 72]. For comparison, commercially available preparations of BSA 
usually contain 5–20% of covalent multimeric water soluble aggregates [73]. We 
could show that 74% and 64% of OVA released from PLGA and Chit-PLGA NPs 
respectively bind to a monoclonal antibody. This allows a conservative estimate of 
the activity of the released OVA as at least the epitope recognized by the primary 
antibody in the ELISA has to be intact. Our results show that despite the formation 
of aggregates during particle preparation the activity of OVA was largely retained. 
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In other words, by applying a usual dose of 8.5 μl NP suspension per cm2 (50 mg 
NPs/ml, 54.3 ± 0.047 and 66.5 ± 0.044 μg OVA/mg NPs, 74% and 64% activity, for 
PLGA and Chit-PLGA NPs respectively) an effective dose of 17 μg/cm2 (PLGA) or 
18 μg/cm2 (Chit-PLGA) of active OVA is administered considering the measured 
loading efficiency and activity of the encapsulated OVA. 
Using OVA loaded PLGA and Chit-PLGA NPs for the stimulation of DCs 
demonstrated that these particles exhibit the capacity to activate murine DCs in 
vitro (Fig. 3). This is a critical step for the development of immune interventions 
based on NPs, since activation and maturation of DCs is recognized as a key 
event in the stimulation of adaptive immune responses [74]. Only marginal 
differences have been observed comparing the expression levels of activation 
markers by DCs stimulated with OVA alone and OVA loaded NPs (Fig. 3). Only 
the number of MHC class II molecules seems to be slightly increased on DCs 
stimulated with Chit-PLGA formulations compared to those stimulated with OVA 
alone. This may be due to the influence of regulatory T cells present in the OT 
splenocyte preparation which was used to for the co-culture with DCs [75]. 
Interestingly, following co-incubation of bone marrow derived DCs with OVA and 
LPS only CD40 expression was increased compared to DCs stimulated with OVA 
alone, whereas in case of all other investigated markers only marginal differences 
have been observed (Fig. 3). In addition, also the capacity of LPS stimulated DCs 
to promote T cell proliferation was marginal (Fig. 4). One possible explanation 
might be a contamination of the assay with IL-10 which was shown to inhibit the 
expression of TLR4 by DCs which subsequently prevents their activation by the 
TLR4 agonist LPS [76]. The source of IL-10 could be bone marrow-derived 
macrophages which were left in the DC population prepared from murine bone 
marrow and which were shown to produce IL-10 by stimulation with LPS [77]. 
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Nevertheless, DCs stimulated with OVA loaded NPs were able to stimulate a 
strongly enhanced clonal expansion of OVA-specific CD4+ OT-II cells compared to 
those stimulated with OVA protein alone. However, only Chit-PLGA NPs were able 
to also promote an enhanced proliferation of OVA-specific CD8+ OT-I cells (Fig. 
4). An obvious difference between PLGA and Chit-PLGA NPs which both have 
similar size/shape/OVA loading/Ova stability is their opposing surface charge 
(Table 1). This leads to conclude that the positive particle charge, which generally 
improves cellular adhesion, internalization, and endosomal escape, may be a 
reason for the superiority of the Chit-PLGA NPs to promote CD4+ and CD8+ 
proliferation [78]. A preferred stimulation of CD8+ T cells may further be expected 
upon transfollicular application [17, 55]. Antigen uptake by DCs and induction of 
DC maturation by Chit and PLGA NPs has been investigated by other groups as 
well but shows inconclusive results, unfortunately also concerning the absence 
[79] or presence of an effect of particle surface charge [80]. This indicates that in 
addition to the surface charge also the composition of the NPs may play a role [81, 
82]. The composition (e.g. degree of substitution, chain length) of the biopolymer 
chitosan depends on the source of manufacturer as well as varies from batch to 
batch which makes it difficult to compare between studies. 
The adoptive transfer model is a well-established tool to characterize T cell 
activation in vivo, since TCR-transgenic mice are tolerogenic to their TCR specific 
Ag (reviewed in [83]). In the present study adoptive transfer experiments were 
performed to analyze the transfollicular vaccination route in comparison with the 
i.m. route in an in vivo setting. Transfollicular immunization and subsequent 
analysis of the triggered immune responses in the draining lymph nodes and 
secondary lymphatic organ four days after immunization appealed as the most 
suitable technique to assess proliferation of the transferred cells. Indeed, 
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transfollicular administered OVA in Chit-PLGA NPs+ c-di-AMP as adjuvant elicited 
strong OT-II cell proliferation. The fact that more cell divisions were observed after 
transfollicular administration of Chit-PLGA-OVA NPs compared to those observed 
following i.m. administration of OVA alone provides evidence that combination of 
OVA with NPs activated the OVA-specific cells more efficiently which resulted in 
enhanced proliferation. Future immunization studies with disease relevant 
antigens need to show whether a potent immune response can be elicited by 
transfollicular vaccination without the use of barrier disrupting methods. It should 
be kept in mind that secondary to permeabilizing the skin, tape stripping or other 
barrier disrupting methods activate the innate immune response and thus work as 
an unspecific adjuvant. This includes the secretion of the proinflammatory 
cytokines TNF-α, IL-1α, IL-1β, and GM-CSF by keratinocytes. TNF-α and IL-1β 
trigger the upregulation of the expression of a6 integrins, intercellular adhesion 
molecule 1 (ICAM.1), CD86 and MHC class II molecules which then promote the 
dissociation of LCs from keratinocytes, their subsequent maturation and migration, 
and improves the antigen-specific immune responses [22, 59, 84]. The use of 
immune-stimulating molecules or adjuvants in the formulation is an alternative to 
further optimize the elicited immune responses. This may become important to 
overcome the tolerogenic potential of the perifollicular LCs and dermal DCs. 
Mattheolabakis et al. showed that TCI with OVA encapsulated in poly(lactic acid) 
NPs was less immunogenic than soluble OVA, however by the addition of the 
adjuvant cholera toxin boosted the immunogenicity of the NP formulation over that 
of soluble antigen [85]. 
 
While the immunological response towards vaccines is foremost evaluated in 
different mouse models, rodent skin is not appropriate for testing transdermal 
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delivery and especially transfollicular penetration. Mouse SC has a different 
corneocyte architecture as well as lipid composition and arrangements, leading 
mouse skin to be more leaky and therefore an inappropriate surrogate for 
transdermal delivery in man [86]. With special regards to their hairs, mice have a 
higher follicular density than man while pig and man resemble each other more 
closely (mouse: >5000 cm2, pig: ca. 22 cm2, human ca. 25 cm2 on the forearm) 
[87, 88]. Due to the limitations the mouse model represents, we also investigated 
the delivery of nano-encapsulated OVA to terminal follicles on the porcine ear. Pig 
skin is an appropriate substitute for human skin, pig ears are the gold standard 
model for investigating follicular penetration [89]. The ear cartilage prevents tensile 
fibres from irreversibly closing the follicle openings which drastically reduces 
follicular uptake in excised human skin [90]. 
For transfollicular vaccination it will be essential that the delivery efficiency into the 
hair follicle is high, i.e. that major parts of the dose are delivered to the peri-
follicular APCs. We observed the distribution of the NPs on the skin surface and 
within the follicular duct (Fig. 7). The real invasion depth into the follicle remains 
elusive from these images as only the upper part of the follicle is visible in the 
cross-section. It requires an extensive number of consecutive cuts to obtain 
reliable measurements due to the angular orientation of the hairs inside the skin 
[11, 91]. We observed 2–3 times higher drug amounts in the hair follicles if OVA 
was encapsulated in NPs compared to solution. The follicular uptake efficiency 
could further be increased by increasing the NP dose/area. No significant 
differences were observed in the follicular uptake of PLGA and Chit-PLGA NPs 
(Fig. 8a). Both NPs have a similar size and size distribution but opposite surface 
charges. These results are in line with the study by Patzelt et al. who suggested 
that the invasion depth into the follicles depends foremost on NP size and less on 
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particle surface properties [11]. In general, follicular uptake of microparticles is 
preferred [92]. For terminal hairs in pigs the optimum particle size for deep 
penetration was found to be 650 nm [11, 91]. The data presented in this work 
further underline the great potential of NPs to improve transfollicular vaccination as 
compared to administering the “naked” antigen across the intact SC. 
2.6. Conclusion 
In conclusion OVA protein could be incorporated with only moderate loss of 
biological activity into NPs made from PLGA and Chit-PLGA. Encapsulation 
increases the delivery of OVA to the follicle by a factor of 2 to 3 and can be further 
increased by increasing the dose of particles applied by area. No pretreatment 
such as plucking the hairs, waxing or superglue stripping was required to achieve 
a follicular uptake so that the SC barrier was left intact. Deep penetration into the 
follicles by the help of NPs delivers the antigen into the vicinity of the perifollicular 
APCs. OVA loaded PLGA and Chit-PLGA NPs were able to stimulate efficiently 
murine DCs and subsequently antigen-specific CD4+ and CD8+ T-cells. An 
adoptive transfer experiment demonstrated that the model antigen OVA can be 
delivered via the transfollicular route and that the immunization by this route is 
able to elicit the same proliferation of OVA specific CD4+ T cells as the i.m. 
injection of OVA. Thus, transfollicular delivery seems a promising opportunity 
vaccination strategy under critical hygienic conditions, for example in individuals 
with impaired immune system or the elderly. 
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3.1. Abstract 
Trans-follicular (TF) vaccination has recently been studied as a unique route for 
non-invasive transcutaneous vaccination. The present study aims to extensively 
characterize the immune responses triggered by TF vaccination using ovalbumin 
loaded chitosan-PLGA nanoparticles without skin pre-treatment to preserve skin 
integrity. The impact of formulation composition i.e. antigenic solution or antigen-
loaded nanoparticles with or without adjuvant (bis-(3',5')-cyclic dimeric adenosine 
monophosphate) on immune response quality following TF immunization was 
analysed and compared with immune responses obtained after tape-stripping the 
skin. The results presented in this study confirm the potency of nanoparticle based 
vaccine formulations to deliver antigen across the intact skin via the follicular 
route, but at the same time demonstrate the necessity to include adjuvants to 
generate efficient antigen-specific humoral and cellular immune responses. 
 
3.2. Introduction 
Vaccination is one of the most promising strategies to prevent infectious diseases. 
Its potential therapeutic use against communicable and non-communicable (e.g. 
cancer) diseases is also attracting considerable interest. However, to meet the 
current challenges of vaccine delivery an easy-to-use, needle-free and non-
invasive delivery system is needed [22]. In this perspective, transcutaneous 
immunization (TCI) offers an attractive approach for the development of highly 
accepted and needle-free vaccines, which are not only safe but also effective due 
to the presence of abundant professional antigen presenting cells (APCs), such as 
dendritic cells (DCs) and Langerhans cells (LCs), in different layers of the skin.  
However, the main challenge for TCI is to enhance the transport of antigens 
across the stratum corneum (SC) barrier. To this end, reversible barrier disruption 
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methods are often applied, such as chemical permeation enhancers, abrasion, 
electroporation, micro-needles, PowderJect and gene gun [93]. In contrast, TF 
vaccination aims to deliver antigens to the abundant peri-follicular APCs without 
compromising the SC barrier function [14]. Nanoparticles (NPs) have been shown 
to be ideal vehicles for TF delivery, since they preferentially accumulate and 
penetrate deeper into hair follicles than conventional formulations [19]. In our 
previous studies, we have shown that this holds also true in case of delivery of 
antigenic molecules encapsulated into NPs not only in terms of penetration of 
antigen in hair follicles but also quantitatively. We observed 2–3 times higher 
antigen amounts in the hair follicles of excised pig ear skin, when the antigen had 
been encapsulated in NPs as compared to antigen applied as solution [12].  
However, TF vaccination is usually performed after pre-treating the skin area by 
plucking hairs, waxing or cyanoacrylate (superglue) stripping [15, 56, 94]. Pre-
treatment not only permeabilizes the skin by removing the upper layers of the SC, 
but also activates the innate immune system [22]. Both factors probably improve 
the immunogenicity of a topically applied vaccine. On the downside also 
pathogens can possibly overcome the permeabilized SC, which makes these 
strategies suboptimal for various purposes, for example mass vaccination 
campaigns or vaccination of immune-compromised individuals, elderly, people 
with poor wound healing or young children.  
Our previous studies investigated the potential of the TF route for the delivery of 
antigen using NPs without pre-treating the skin for the purpose of non-invasive 
TCI. As a proof of concept, we showed the successful delivery of antigen via the 
TF route using antigen-loaded NPs in an adoptive transfer mouse model by 
measuring the proliferation of antigen-specific CD4+ T cells [12]. Although the 
adoptive transfer model demonstrated the viability of this vaccination route, the 
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experimental setting does not resemble a true vaccination. The proliferation of 
ovalbumin (OVA)-specific CD4+ T cells provides a hint on the feasibility of this 
approach. However, while in a normal mouse antigen-specific T cells are 
supposed to be in a ratio of 1 in 100,000, this ratio is artificially elevated to at least 
1 in 100 by the adoptive transfer method. 
Here, we extended our in vivo mouse studies in a normal vaccination setting to 
confirm the viability of the TF route, as well as to obtain deeper insights in the 
immune responses generated using NPs without pre-treatment of the skin. To this 
end, vaccination experiments were performed in conventional mice in which i) skin 
integrity and maintenance of the skin barrier function was monitored throughout 
the experiment, ii) immune responses generated by applying different formulations 
on tape stripped and intact skin were compared, and iii) immune responses 
generated by applying antigen-loaded NPs on skin without compromising the SC 
barrier in the presence or absence of an adjuvant were extensively characterized. 
The obtained results should assist in the rational designing of particulate 
formulations for prophylactic or therapeutic vaccination via the TF route. 
 
 
3.3. Materials and methods 
3.3.1. Materials 
EndoGrade® OVA was obtained from Hyglos GmbH (Bernried, Germany); 
poly(d,l-lactide-co-glycolide) (PLGA) (Resomer RG 50:50 H; inherent viscosity 
0.31 dl/g) was kindly provided by Boehringer Ingelheim (Boehringer Ingelheim 
GmbH & Co., KG, Ingelheim, Germany). c-di-AMP (C20H24N10O12P2) was 
synthesized by cyclization, according to established protocols [95]. Polyvinyl 
alcohol (PVA) Mowiol® 4–88 was obtained from Kuraray Specialties Europe 
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GmbH (Frankfurt, Germany); ultrapure chitosan chloride salt (Protasan® UP 
CL113) was purchased from FMC BioPolymer AS (Oslo, Norway); trehalose was 
obtained from Sigma–Aldrich (St. Louis, MO, USA); Vybrant DiD cell-labeling 
solution was obtained from Invitrogen (Molecular Probes Inc., Germany). Tesa film 
was obtained from TESA SE, Hamburg, Germany. All other solvents and 
chemicals used were of the highest grade commercially available. Deionized water 
(Milli Q Plus system, Millipore, Bedford, MA, USA) was used throughout the 
investigation. 
3.3.2. Particle preparation  
OVA-loaded Chit-PLGA NPs were prepared by modified double emulsion method 
[12]. Briefly, 50 mg of PLGA were dissolved in 2 ml of ethyl acetate at room 
temperature (RT). Then, 400 µl of (1.875% wt/V) OVA solution in PBS was added 
to form a primary water-in-oil (w/o) emulsion. After sonication at 6 W for 15 s, 4 ml 
of 2% (wt/V) PVA and Protasan® UP CL113 (0.2% wt/V) solution was added to 
the primary emulsion which was again sonicated at 8 W for 20 s. Water was added 
drop-wise to the resulting w/o/w emulsion under constant stirring to allow diffusion 
and evaporation of the organic solvent. The particles were collected by 
centrifugation at 10,000 × g for 15 min, washed once with distilled water to remove 
excess surfactant and free drug and freeze dried using trehalose (0.2% wt/V) as 
cryoprotectant.  
3.3.3. Mice 
Female C57BL/6 (H-2b) mice 6–8 weeks old were purchased from Harlan 
Germany. All animal experiments in this study have been performed with ethical 
agreement by the local government of Lower Saxony (Germany) with the No. 
33.11.42502-04-017/08. 
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3.3.4. Measurement of transepidermal water loss (TEWL) 
TEWL was assessed on the dorsal side of flank part of four C57BL/6 mice skin 
using an AquaFlux AF200 which operates with a closed measurement chamber 
(Biox Systems Ltd., London, UK). Measurements of TEWL were taken on day 0 (of 
untreated skin, serving as control reading, and again after performing depilation), 
on day 1 and day 2, according to the manufacturer’s instructions. 
3.3.5. Immunization protocols 
Immunization was carried out on the flanks of the mice. In brief, 2 days before the 
immunization mice were anesthetized and hair was removed using clippers and a 
depilatory cream. Depilated areas were carefully inspected for cuts or skin 
irritation, in which case these mice were excluded from the experiment.   
Female C57BL/6 mice (n = 5) were immunized on day 0, 14, 28 and 42 by 
applying 60 µl of different formulations containing 200 µg of LPS-free OVA 
topically to an area of 2.25 cm² of either intact or tape stripped skin (Table 1).   
Tape stripping was performed as follows: 5 successive adhesive tapes (Tesafilm 
kristallklar, Tesa SE, Germany) were removed from the application area. For each 
stripping, a fresh piece of tape was lightly pressed onto the skin and subsequently 
pulled off. Directly after stripping, control or vaccine formulations were applied and 
allowed to dry completely. During this procedure the mice remained anesthetized 
to secure optimal uptake of the formulations.   
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Table 1.  
Immunization groups  
S.no. Group Skin condition Dose (OVA ± c-di AMP / µl) 
1 Blank NPs + c-di AMP Intact skin Equivalent to OVA-loaded NPs 
2 OVA Intact skin 200 µg/ 60 µl 
3 OVA Tape stripped skin 200 µg/ 60 µl 
4 OVA + c-di AMP Intact skin 200 µg + 20 µg / 60 µl 
5 OVA-NPs Intact skin 200 µg/ 60 µl 
6 OVA-NPs Tape stripped skin 200 µg/ 60 µl 
7 OVA-NPs+ c-di AMP Intact skin 200 µg + 20 µg / 60 µl 
 
3.3.6. In vivo localization of nanoparticles using histology  
Histo-pathologic studies were performed on skin sites 4 h after topical application 
of DiD loaded Chit-PLGA NPs. Skin sites were removed and immediately 
embedded in O.C.T™ (Tissue-Tek®, Sakura Finetek Germany GmbH, Germany) 
for cryopreservation. Frozen tissues were sequentially sectioned into 6 μm slices 
with a Microm HM 560 cryostat (MICROM International GmbH, Walldorf, 
Germany). Subsequently, sections were stained with DAPI (4´,6-Diamidine-2-
phenylindoledihydrochloride, Roche) and analyzed with a fluorescence 
microscope.  
3.3.7. Sample collection 
Blood samples from immunized mice were taken from the retro-orbital complex on 
day −1, 13, 27, 41 and 56. In order to gain sera from the blood samples were 
incubated for 1 h at 37 °C followed by 30 min incubation at 4 °C. Afterwards, 
samples were centrifuged for 10 min at 3000 × g and sera were stored at −20 °C 
prior to determination of OVA-specific antibodies.  
 On day 56, mice were sacrificed, lymph nodes and spleens were collected and 
single cells were obtained by homogenization of the organs mechanically using a 
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sieve pooled within groups and collectively analysed for the presence of antigen-
specific cells, as previously described [95]. 
3.3.8. Detection of antigen-specific IgG and IgG subtypes 
OVA-specific antibodies in sera of individual animals were determined by ELISA, 
using microtitre plates coated with 100 µl/ well of the antigen (2 µg/ml in 0.05 M 
carbonate buffer, pH 9.6), as previously described [95]. After overnight incubation 
at 4 °C, unspecific binding sites were blocked incubating the plates with 3% bovine 
serum albumin (BSA) in PBS for 1 h at 37 °C. Afterwards, plates were washed 
with 1% BSA/PBS/0.05% Tween 20 and serial 2-fold dilutions of sera in 3% 
BSA/PBS were added (100µl/well). After 1 h incubation at 37 °C plates were again 
washed six times with 1% BSA/PBS/0.05% Tween 20 before the secondary 
antibodies were added: biotinylated γ chain-specific goat anti-mouse IgG or for 
determination of different IgG subclasses, biotinylated goat anti-mouse IgG1 and 
IgG2c (Sigma, USA), respectively,. Subsequently, samples were incubated at 37 
°C for 1 h. After six washing steps, 100 µl of peroxidase-conjugated streptavidine 
(BD Pharmingen, USA) was added to each well and the plates were incubated at 
RT for 1 h. Finally, after another six washes, reactions were developed using 
ABTS [2, 20-azino-bis(3- ethylbenzthiazoline-6-sulfonic acid)] in 0.1 M citrate-
phosphate buffer (pH 4.35) containing 0.01% H2O2. Endpoint titres were 
expressed as absolute values of the last dilution that gave an optical density at 
405 nm that was 2 times higher than the negative control values after a 15 and 30 
min incubation. 
3.3.9. Measurement of cellular proliferation 
Spleen and Lymph node cells of vaccinated mice were obtained by mashing the 
organs and subsequently lysing erythrocytes for 1 min with ammonium chloride 
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(ACK) buffer. After several washes with complete medium (RPMI supplemented 
with 10% fetal calf serum, 100 U/ml penicillin and 100 μg/ml streptomycin), cell 
suspensions were adjusted to 5 × 106 cells/ml and seeded at 100 µl/well in flat-
bottomed 96-well microtiter plates (Nunc, Roskilde, Denmark), which were 
incubated in quadruplicates for 4 days in the presence of different concentrations 
of EndoGrade® Ovalbumin (Hyglos, Germany), 5 µg/ml Concanavalin A or 
medium alone [95].During the final 18 h of culture, 1 µCi of (3H)thymidine 
(Amersham International, Freiburg, Germany) was added to each well. Then, cells 
were harvested on paper filters (Filtermat A; Wallac, Freiburg, Germany) by using 
a cell harvester (Inotech, Wohlen, Switzerland) and the relative amount of 
proliferating cells was determined by measuring the beta radiation of (3H)thymidine 
incorporated into the DNA of the cells Wallac 1450 ß-scintillation counter Micro-
Trilux). The obtained results are expressed as stimulation index (SI).  
3.3.10. Evaluation of cytokine profiles 
To quantify the cytokines and chemokines secreted by antigen-specific immune 
cells, lymphocytes and splenocytes were re-stimulated in vitro with different 
concentrations of EndoGrade® OVA (Hyglos, Germany). After 96 h of incubation 
supernatants were collected and stored at −80 °C until processing. Then, the 
amounts of IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, TNFα and IFN were 
determined using the Mouse Th1/Th2 FlowCytomix cytokine array according to the 
manufacturer’s instructions (eBioscience, Bender MedSytems®, USA). 
3.3.11. Multifunctional T cells 
In order to evaluate the capacity of the different vaccine formulations to stimulate 
OVA-specific multifunctional T cells, splenocytes from immunized mice were taken 
and their capacity to produce different cytokines was evaluated by flow cytometry. 
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In brief, splenocytes (2 x 107 cells per well) of immunized mice were incubated (37 
°C, 5 % CO2) in 2 ml RPMI containing OVA protein [1µg/ml]. After 16-20 hours 5 
µg/ml BrefeldinA and 6 µg/ml Monensin (Sigma-Chemie, Germany) were added 
and cells were incubated for additional 6 hours. Subsequently, cells were stained 
for dead cells (Fixable Dead Cell Stain, Invitrogen, USA) and surface markers 
(CD3 and CD8, BD, USA; CD4, eBioscience, Germany). Then, cells were fixed 
with 2 %PFA, permealized for 45-60 min with 0.5 % BSA and 0.5 % Saponin in 
PBS and stained for intracellular cytokines (IL-2 and IFN, BD, USA; TNFα, IL-17 
and IL-4, eBioscience, Germany). Finally, cells were resuspended in PBS and light 
emission measured using BD LSRII. After spectral overlap compensation with the 
BD FACS Diva Software, the data were analyzed using FlowJo (Tree Star, USA) 
3.3.12. Statistical analysis 
The statistical significance of the differences between experimental groups was 
analysed using one way ANOVA. Differences were considered significant at 
p<0.05 (*) and highly significant at p<0.001(***).   
 
 
3.4. Results 
3.4.1. Characterization of OVA-loaded Chit-PLGA NPs 
The characteristics of the NPs are summarized in Table 2. The mean size of OVA-
loaded Chit-PLGA NPs was ca. 180 nm and a monodisperse size distribution (PDI 
< 0.2). The particles carried a positive surface charge and had an entrapment 
efficiency (wt OVA encapsulated/wt OVA added initially) of 30.85% ± 1.08% and % 
loading (wt OVA encapsulated/wt polymer) 6.65 % ± 0.18%. Admixing the 
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adjuvant to the OVA-loaded NPs did not change the particle characteristics in 
terms of size and charge.  
Table 2 
Physico-chemical characterization of the optimized Chit-PLGA NPs 
Nanoparticle Size (nm) PDI Z.P. (mV) % EE % L 
Blank Chit-PLGA 163.8 ± 
3.36 
0.093 ± 
0.012 
33.1 ± 
1.02 
- - 
OVA-loaded Chit-
PLGA 
168.2 ± 
4.71 
0.135 ± 
0.023 
27.7 ± 
1.05 
28.54 ± 
1.08 
6.65 ± 
0.18 
Values represent mean ± standard error of the mean (SEM) of n = 4 independently prepared 
batches, Z.P. zeta potential, %EE encapsulation efficiency (wt OVA encapsulated/wt OVA added 
initially), %L loading (wt OVA encapsulated/wt polymer) 
 
3.4.2. TEWL Measurement   
TEWL measures the skin barrier towards water and is a well-established non-
invasive tool in dermatology to assess the integrity of the skin barrier in vivo and 
for testing skin irritancy [96]. Its high sensitivity allows detecting clinically invisible 
damage to the skin induced by various physical and chemical injuries. When skin 
is damaged, its barrier function is impaired resulting in higher trans-epidermal 
water loss. To evaluate if the skin barrier was intact on the day of immunization, 
i.e. 2 days after depilation, TEWL was measured before treatment, directly after 
depilation and on two subsequent days. Just 30 min after depilation, the TEWL 
measurement of the depilated area was twice that of normal untreated skin, 
thereby showing the barrier disruption via this procedure even in the absence of 
any visible cut or irritation of the skin. As shown in Fig. 1, the skin barrier 
recovered to its normal value within 2 days of the depilation procedure. 
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A 
 
 
B 
 
Figure 1. Determination of the integrity of the skin at different time points according to TEWL 
measurements. A) Normalized TEWL measurement at different time points. B) Individual TEWL 
measurement at different time points (n=4). Standard deviation (STD) is indicated by vertical lines  
 
3.4.3. In vivo localization of nanoparticles using histology 
Applying antigenic solutions onto intact skin usually does not result in the 
stimulation of immune responses as the SC forms a barrier towards penetration of 
foreign substances. However, NPs are preferentially taken up into hair follicles and 
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accumulate in the upper duct (infundibulum). Fig. 2 shows a representative image 
illustrating the distribution of DiD (fluorescently dye) loaded Chit-PLGA NPs on the 
skin surface and in the hair follicle after application to mice skin. It is apparent that 
the NPs accumulated in the follicle openings, cover the hair and invade into the 
follicular duct.  
LCs, which are natural residents of the epidermal sheath surround the hair follicle 
[97], get in contact with the antigen-loaded NPs resulting in stimulation of immune 
responses [55]. In line with these observations, NPs incorporated in our vaccine 
formulations also reached the upper hair-follicular duct and thus, most likely can 
be taken up by local LCs (Fig. 2). 
 
 
Figure 2. Localization of DiD loaded Chit-PLGA NPs 4 h after topical application on the skin of the 
flank of mice. The analysis of cryosections (6 µm) showed NPs (red) which are visible on the skin 
surface and penetrate inside the hair follicles. Scale bar: 50 µm. Cell nuclei were stained with DAPI 
(blue) 
Transcutaneous vaccination via hair follicles using NPs requires adjuvantation  
 
61 
 
3.4.4. Humoral immune response (total IgG, IgG1 and IgG2c) 
Serum anti-OVA IgG antibody levels obtained after TF vaccination with OVA and 
OVA-loaded NPs with or without co-administration of bis-(3',5')-cyclic dimeric 
adenosine monophosphate (c-di-AMP) as adjuvant on intact or tape stripped skin 
are shown in Fig. 3A. OVA alone applied onto the intact skin or tape stripped skin 
promotes very low IgG titres. However, stripping the skin results in significantly (p 
<0.5) increased IgG titres for OVA-loaded NPs as compared to OVA-loaded NPs 
applied on intact skin. OVA + c-di-AMP applied on intact skin also promoted low 
IgG titres. Interestingly, OVA-loaded NPs + c-di-AMP applied on intact skin 
stimulated significantly increased (p <0.5) OVA-specific IgG titres in comparison to 
all tested formulations, except OVA NPs applied onto the tape stripped skin. For 
mice immunized with OVA loaded NPs + c-di-AMP, the difference in OVA-specific 
IgG titres after priming and the 1st boost were less distinct. However, after the 2nd 
and 3rd boost significantly increased titres (p<0.001) were obtained in comparison 
to all tested groups, except OVA NPs applied on tape stripped skin after 2nd boost 
(p<0.05) (Fig. 3B). 
The ratio of IgG1:IgG2c is an indication on whether the cellular immune response 
is Th1 or Th2 biased. All groups receiving OVA alone or OVA-loaded NPs applied 
either on intact skin or tape stripped skin mainly showed anti-OVA IgG1 but not 
IgG2c (i.e. Th2 biased responses). However, admixing the adjuvant with the NPs 
resulted in significantly increased levels of the IgG2c subclass (i.e. Th1) when 
applied on intact skin (Fig. 3C). 
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Figure 3. Systemic humoral immune responses stimulated in C57BL/6 mice (n = 5) after four 
vaccinations with different OVA-containing formulations via intact and tape stripped skin. (A) OVA-
specific IgG titres in sera after immunization (n = 5). (B) Kinetic analysis of OVA-specific IgG titres 
in sera of immunized mice on day 10, 30, 50 and 68. (C) Analysis of OVA-specific IgG subclasses 
stimulated in mice following immunization with different OVA-containing vaccine formulations. 
Results are expressed as log2 of the last dilution giving the double value (OD450 nm) of the 
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background value (negative control). Standard error of mean (SEM) is indicated by vertical lines. 
Differences were considered significant at p<0.05 (*) and p<0.001 (***), respectively. 
 
3.4.5. Measurement of cellular proliferation 
The stimulation of cellular immune responses in mice after immunizing them with 
different OVA formulations on intact and tape stripped skin was then analysed. To 
this end, lymph node cells and splenocytes were re-stimulated in vitro with 
different concentrations of OVA for 96 h and cellular proliferation was determined 
by measuring the incorporation of [3H] thymidine.  
The strongest proliferative capacity was observed for lymphocytes derived from 
mice immunized with OVA-loaded NPs co-administered with c-di-AMP, as 
demonstrated by the Stimulation Index (Fig. 4). In contrast, lymphocytes of mice 
immunized with OVA alone or OVA-loaded NPs showed no proliferative capacity 
when re-stimulated with OVA. A similar pattern was observed with splenocytes. 
 
Figure 4. Evaluation of the cellular responses stimulated in mice after four vaccinations with 
different OVA-containing formulations via intact and tape stripped skin. Lymph node cells from 
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vaccinated animals were restimulated with different concentrations of OVA for 96 h. Cellular 
proliferation was then assessed by determination of the [3H] thymidine incorporated into the DNA 
of replicating cells. Results are averages of quadruplicates and they are expressed as stimulation 
index (SI). The differences were considered significant at p<0.01 (**) and p<0.001 (***), 
respectively. 
 
The cytokine secretion profiles of lymphocytes from vaccinated mice was then 
analysed by cytometric bead arrays (Fig. 5). Again, the strongest cytokine 
production was observed in mice immunized with OVA-NPs co-administered with 
c-di-AMP (Fig. 5). No differences were observed in the cytokine profiles of groups 
receiving OVA protein via the TF route with highest levels of IL-13 followed by IL-
5, and IL-10. Thus, indicating a Th2-dominated immune response. When OVA 
protein was co-administered with c-di-AMP production of IL-17, IL-4 and IFN was 
also stimulated, indicating a mixed Th1/Th2/Th17 response (Fig. 5). Interestingly, 
the same was true when analysing the profiles stimulated by OVA-NPs applied 
either via intact or tape stripped skin. Strong IFN production (Th1 response) was 
only achieved by tape stripping the mouse skin prior to immunization with OVA-
NPs. The necessity of breaching the skin barrier in order to elicit efficient immune 
response can be overcome by co-administration of OVA-NPs with c-di-AMP (Fig. 
5). 
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Figure 5. Analysis of cytokines secreted by immune cells of vaccinated mice. Cells were re-
stimulated in triplicates with different concentrations of OVA for 96 h. Results are expressed in 
pg/ml. Standard error of mean (SEM) is indicated by vertical lines.  
 
3.4.6. T cell quality following vaccination  
Beside the magnitude of cellular responses, vaccine efficacy also depends on the 
quality of the stimulated antigen-specific T cell responses. There is consensus that 
multifunctional T cells are associated with enhanced protection against infection, 
likely based on a broader functional spectrum [98].  
Thus, the quality of the T cell responses stimulated by different vaccination 
regimes was investigated. Immunization via the TF route stimulated only single 
(IFN+) and double positive (IFN+/TNFα+, IFN+/IL-2+) antigen-specific CD8+ T 
cells (Fig. 6A). 
Transcutaneous vaccination via hair follicles using NPs requires adjuvantation  
 
66 
 
Interestingly, only in mice tape stripped prior to vaccination increased numbers 
were observed whereby IFN+/TNF+ double positive CD8+ T cells constitute the 
predominant subset. However, as shown for the stimulated cytokine profiles, co-
administration of c-di-AMP with OVA-NPs not only elicits strong Th1/Th2 
response, but also resulted in the strongest stimulation of antigen-specific CD8+ 
responses (Fig. 6A). When analysing the quality of the stimulated CD4+ 
responses, it is even more obvious that only incorporation of c-di-AMP results in 
efficient cellular responses (Fig. 6B). Furthermore, co-administration of OVA-NPs 
with c-di-AMP efficiently stimulated multifunctional double (IFN+/TNFα+, IFN+/IL-
2+) and triple positive (IFN+/TNFα+/IL-2+) CD4+ cells (Fig. 6B). In accordance 
with the results obtained analysing the IgG subclasses as well as the cytokine 
profiles and proliferative capacity of antigen-specific cells, vaccination via the TF 
route seems to favour the stimulation of multifunctional CD4+ rather than CD8+ T 
cell responses. 
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Figure 6. T cell responses stimulated following vaccination via TF route. Cells were collected at day 
14 after the last immunization and subsequently incubated for 24 h in the presence and absence of 
OVA. Results are expressed as difference between re- and non-restimulated % of all CD8+ and 
CD4+ cells, respectively, expressing IFN. Living cells were gated for CD3+ CD8+ and CD3+ CD4+ 
double positive cells, respectively. These subpopulations were further divided into monofunctional 
expressing only IFN, bifunctional expressing two cytokines (IFN / IL-2 or IFN / TNFα) and 
trifunctional expressing IFN, IL-2 and TNFα. Pie charts represent the proportion of tri- (black), bi- 
(dark gray) and mono-functional (light gray) cells.  
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3.5. Discussion 
It is quite evident in literature that skin is an attractive organ for immunization that 
can be easily manipulated for vaccination purposes. Recently, the topical delivery 
of antigens formulated into particulate delivery systems has evoked considerable 
interest. NPs have been shown to be promising carriers for TCI and for modulating 
the immune response depending on the site of delivery [55]. In particular, TF 
vaccination using NPs holds potential for non-invasive and needle-free vaccine 
delivery without disrupting the barrier properties of the skin. It has been shown that 
NPs of a size of approx. 200 nm were taken up by the LCs lying around the hair 
follicles [56].  
TCI with antigen (gp100 protein) loaded chitosan NPs was shown to improve the 
survival of tumour bearing mice in comparison to antigen solution [99]. However, it 
was unclear from these studies, if the particles were applied on intact or tape 
stripped skin [99]. Stripping results not only in mild to moderate skin disruption, but 
also activates the innate immune system [12, 22, 100]. Mattheolabakis et al. 
showed the efficacy of TCI following a prime-boost protocol using OVA-loaded 
poly-lactic acid NPs [85]. Mice received a priming and a 1st boost immunization 
via the topical route, whereas the 2nd boost was administered via the 
subcutaneous route [85]. However, whether the outcome after immunization using 
NPs reflects superiority compared to antigen solution, the true potential of TF 
immunization in terms of overall magnitude of antibody response and its 
subclasses, kinetics, cytokines release profiles, cellular response, and many other 
factors still remained ambiguous. In the present study an in depth characterisation 
of the immune responses stimulated after TF immunization using NPs as a 
needle-free vaccination strategy without any barrier disrupting measure is 
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described. This is crucial, since even modest barrier disruption is 
immunostimulatory and may confound the effects resulting from antigen or antigen 
loaded delivery systems.  
For this purpose it is essential to demonstrate skin integrity and the maintenance 
of skin barrier function throughout the experiment. A critical step is the hair 
trimming and depilation procedure which is necessary in order to provide an even 
field onto which the formulation can be applied homogeneously. We tested the 
integrity of skin using TEWL measurement before and after depilation and for the 
following 2 days. Interestingly, we found that TEWL measurements doubled those 
of the normal untreated skin after 30 min of depilation. This shows the barrier 
disruption caused by this procedure, even without any visible cuts or redness 
which could indicate skin damage or irritation. This demonstrates the sensitivity of 
TEWL measurement for testing the barrier function of the skin towards water, 
which makes it suitable to detect also transient damage to the skin barrier. The 
skin seemed to recover fully within 2 days of depilation, as TEWL values returned 
to the baseline levels observed before depilation. Therefore, this study revealed 
that careful analysis of the skin barrier integrity is mandatory before applying the 
formulation on depilated skin. This is particularly important considering that, 
according to the literature, formulations are often applied immediately or within 30 
min of depilation [85, 99]. 
Humoral immune responses observed after applying different vaccine formulations 
on intact and tape stripped skin were compared. OVA-loaded NPs applied on tape 
stripped skin promoted significantly higher anti-OVA IgG titres in comparison to 
OVA-loaded NPs applied on intact skin. This result is in agreement with the 
studies done by Li et al. showing an increase of IgG response after stripping the 
skin which might be due to mild barrier disruption or immunostimulation caused by 
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tape stripping [101]. However, co-administering an adjuvant (c-di-AMP) along with 
OVA-loaded NPs applied on intact skin promoted the highest IgG titres among all 
tested formulations. In contrast, only low IgG titres were observed for OVA + c-di-
AMP when applied on intact skin, thereby indicating that the capacity to induce 
strong humoral immune responses depends on the synergistic effect of combining 
NPs and adjuvant in the formulation. This potentiated immune response may be 
explained by: i) enhanced delivery of antigen to hair follicles when encapsulated 
into NPs, as shown in our previous work,5 and ii) activation of the LCs lying near 
to hair follicles by the adjuvant present in the formulation which acts as a danger 
signal, thereby promoting LCs activation, motility and dendritic probing, and 
directed migration and entry into lymphatic vessels [102]. 
In line with previous reports showing that OVA alone applied onto intact or tape 
stripped skin generates predominantly the production of IgG1 [103] similar results 
were obtained in case of OVA-loaded NPs, which also stimulated mainly the 
production of IgG1. In order to evaluate the impact of adjuvant not only to 
strengthen the OVA-specific immune responses but also to modify them in terms 
of cellular and humoral direction, we co-administered c-di-AMP along with OVA 
solution and OVA loaded NPs onto intact skin. This adjuvant is known to stimulate 
balanced Th1/Th2 responses when applied via the mucosal or systemic route 
resulting in the generation of cytotoxic responses as well [95]. Interestingly, when 
OVA protein was applied together with c-di-AMP on the intact skin, no modification 
of the T helper cell response was stimulated as indicated by the observed IgG1 
dominated response (Th2). In contrast, when mice received OVA-NPs + c-di-AMP 
a balanced IgG1/IgG2c response (Th1/Th2) was stimulated, indicating a 
synergistic effect by combining NPs and adjuvant in the formulation via this route. 
This synergistic can be explained by the improved efficiency in delivery of antigen 
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and adjuvant to the perifollicular antigen presenting cells in comparison to 
solutions. This is in line with reports by Mahe et al. showing improved uptake and 
translocation of nano-encapsulated antigen via the hair follicles [56]. Similarly 
Kahlon et al. observed that modification of the immune response stimulated in 
mice following TCI with OVA using cholera toxin as adjuvant was achieved only 
when animals were tape stripped prior to vaccination, i.e. only after damaging the 
skin barrier and thus enabling transcutaneous OVA/adjuvant delivery [104].  
These results were confirmed by the analysis of the cytokines produced by 
lymphocytes of immunized mice. Only cells derived from mice immunized with 
OVA-NPs + c-di-AMP secreted significant amounts of both the Th1 cytokine IFN 
and Th2 cytokines IL-4, IL-5 and IL-13, thereby reflecting a mixed Th1/Th2 
response. In contrast, cells derived from all other groups secreted mainly IL-13 
followed by IL-5 and IL-17, and showed only marginal levels of IFN. The observed 
cytokine profiles also correlate with findings showing that Th2 biased immune 
responses recruit eosinophils from bone marrow and blood to the sites of 
inflammation [105]. Eosinophils were shown to act as antigen-presenting cells 
which interact with CD4+ T cells resulting in the production of IL-4, IL-5 and IL-13 
by the latter [106-108]. Furthermore, Roth et al. have shown that the shape of T 
helper responses stimulated in skin diseases do not depend on the eosinophil-
specific IL-5, but on the levels of IL-13 and IFN, respectively [109]. This would 
further explain the mixed Th1/Th2 response stimulated by TF immunization of 
mice with OVA-NPs plus c-di-AMP observed here. Taken together, to stimulate not 
only strong antibody and Th2 responses following TF immunization, but also 
efficient Th1 and CD8+ responses vaccination regimes it is required to incorporate 
adjuvants which further promote cellular responses.     
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TF immunization of mice with OVA-NPs + c-di-AMP formulation stimulated not 
only antigen-specific antibody responses, but also CD8+ T cell responses. In line 
with previous reports, CD8+ responses were stronger in mice tape stripped prior to 
vaccination with OVA or OVA-NPs [55]. However, co-administration of c-di-AMP 
surpassed skin disruption and stimulated the strongest antigen-specific CD8+ 
responses. Furthermore, this formulation also stimulated multifunctional CD8+ T 
cells, which were shown to be more efficient in terms of killing as compared to 
single producers [110, 111]. More specifically, TF immunization via intact skin with 
OVA-NPs + c-di-AMP stimulated CD8+ T cells that secrete both IFN and IL-2, 
followed by equal levels of those secreting IFN and TNFα. While IL-2 is needed in 
order to expand T cell responses which in turn could enhance CD8+ T cell 
memory, IFN and TNFα co-producers have enhanced cytolytic activity [112, 113]. 
In addition, OVA-NPs co-administered with c-di-AMP via the TF route also 
stimulated antigen-specific multifunctional CD4+ T cells. These cells were shown 
to be essential, rather than CD8+ T cells, in order to protect against Chlamydia 
infection and tuberculosis [114, 115].  
Taken together, the results presented in this study provide the proof-of concept for 
the potential of NP-based TF vaccination as an approach to deliver antigens 
across intact skin. Incorporation of an adjuvant in the formulation seems to be 
essential in order to generate both efficient antigen-specific humoral and cellular 
responses without breaching the skin barrier as well as to modulate such 
responses according to the specific clinical needs. 
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4. Inverse micellar sugar glass nanoparticles as delivery system: 
adjuvant co-encapsulation, and administration route have a major 
impact on immunization outcome   
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4.1. Abstract 
The objective of this study was to evaluate the potential of surfactant based 
inverse micellar sugar glass nanoparticles (IMSG NPs) as a delivery system for 
vaccination using ovalbumin (OVA) as model antigen. It was also evaluated the 
effect of co-encapsulating the adjuvant bis-(3',5')-cyclic dimeric adenosine 
monophosphate (c-di-AMP) on the strength and type of immune response elicited 
after IMSG NPs administration by intradermal, intranasal or transfollicular route. 
Thus, encapsulation of antigen in IMSG NPs resulted in enhanced antigen stability 
and encapsulation efficacy. OVA + c-di-AMP co-encapsulation in IMSG NPs 
resulted in the stimulation of efficient humoral and cellular responses when 
administered via intradermal and transfollicular route. However, only marginal 
immune responses were observed following intranasal administration. The results 
obtained in this study showed the potential of surfactant based IMSG NPs for the 
establishment of intradermal and transfollicular vaccination strategies. 
 
4.2. Introduction 
 Vaccination is considered as the most effective medical intervention introduced in 
human history. New, safe, efficient, minimal invasive and cheap vaccination 
strategies are desperately needed to meet the current challenges in vaccine 
delivery [22]. Among the main vaccination strategies (i.e. live-attenuated, 
inactivated and subunit vaccines), subunit vaccines are considered the safest. 
However, subunit vaccines generally suffer from poor immunogenicity [93]. Novel 
delivery systems and/or alternative routes for administration may be key to 
address this need.  
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A common strategy to improve immunogenicity of subunit vaccine is encapsulating 
antigen into a particulate carrier. Such carriers not only enhance immunogenicity 
due to mimicking the size of microorganisms, but also help by stabilizing protein 
antigens, ensuring their consistent release, enhancing antigen uptake by antigen 
presenting cells (APCs) and allowing co-encapsulation of adjuvants. This results in 
increased antigen-specific immune responses with reduced amounts of antigen 
needed at the same time [116].  
Polymeric nanoparticles (NPs) such as polylactic-co-glycolic acid (PLGA), 
polylactic acid (PLA) and Chitosan-PLGA (Chit-PLGA) have been extensively 
studied as antigen delivery systems [117]. To this end, often emulsion based 
methods are applied to encapsulate antigens into polymeric NPs. However, these 
particles still showed some obstacles in terms of antigen loading capacity and 
incomplete release of encapsulated antigen. Furthermore, during the NP 
preparation process, protein-based payloads may be exposed to several process- 
and storage-related stresses (such as liquid/liquid and solid/liquid interfaces), 
which result in significant degradation, loss of bioactivity and safety concerns [118, 
119]. Recently, Giri et al. showed a generic approach for efficient incorporation 
and stabilization of proteins for tissue engineering and drug delivery using 
principles from enzyme chemistry and bio-pharmaceutics [120]. In this approach, 
proteins were protected from nonpolar solvent exposure by dispersing them in 
organic solution of surfactants, subsequently freeze drying them and finally 
reintroducing them into polymer solutions and organic solvents for tissue 
engineering.  
In this study, we extended and modified this approach and prepared antigen-
loaded NPs by efficient incorporation and stabilization of antigen using an inverse 
micellar technique and pharmaceutical excipients (surfactants, sugars and oil, 
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generally regarded as safe (GRAS) listed). These inverse micellar sugar glass 
(IMSG) NPs were finally dispersed in an oily dispersion and subsequently 
characterized physico-chemically in terms of size, surface charge and morphology. 
Prior to their in vivo evaluation as vaccine delivery system, the integrity and 
biological activity of the encapsulated antigen was monitored. To assess if 
incorporation of an adjuvant will further enhance the efficacy of the vaccine 
formulation, bis-(3',5')-cyclic dimeric adenosine monophosphate (c-di-AMP) was 
co-encapsulated. 
Administration of antigenic solutions and particulate carriers by intradermal (ID) 
and intranasal (IN) route has been widely studied [116, 121]. However, recent 
attention focuses on non-invasive transcutaneous vaccination strategies. Thus, we 
previously explored the transfollicular (TF) route as potential immunization route 
using ovalbumin (OVA) loaded Chit-PLGA NPs co-admixed with c-di-AMP as 
adjuvant. The obtained results showed the stimulation of efficient immune 
responses without disrupting the skin barrier [12]. Therefore, in the work presented 
here antigen-loaded IMSG NPs with and without co-encapsulated adjuvant were 
evaluated as potential vaccine delivery systems. To this end, mice were 
immunized via intranasal, intradermal and transfollicular route, as the route of 
administration also plays a vital role in generating efficient immune responses. 
 
4.3. Materials and methods 
4.3.1. Materials 
Phospoholipon 85G was kindly provided by Lipoid (Lipoid GmbH, Germany), Span 
80 and trehalose was obtained from Sigma-Aldrich (St. Louis, MO, USA); 
EndoGrade® Ovalbumin (OVA) was obtained from Hyglos GmbH (Bernried, 
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Germany); poly(d,l-lactide-co-glycolide) (PLGA) (Resomer RG 50:50 H; inherent 
viscosity 0.31 dL/g) was kindly provided by Boehringer Ingelheim (Boehringer 
Ingelheim GmbH & Co. KG, Ingelheim, Germany); bis-(3',5')-cyclic dimeric 
adenosine monophosphate c-di-AMP (C20H24N10O12P2) was synthesized by 
cyclization, according to established protocols [95]. Polyvinyl alcohol (PVA) 
Mowiol® 4-88 was obtained from Kuraray Specialties Europe GmbH (Frankfurt, 
Germany); ultrapure chitosan chloride salt (Protasan® UP CL113) was purchased 
from FMC BioPolymer AS (Oslo, Norway); fluorescein isothiocyanate conjugated 
ovalbumin (FITC-OVA) was obtained from Invitrogen (Molecular Probes Inc., 
Germany). Superglue was kindly provided by Uhu GmbH & Co.KG, (Bühl, 
Germany). Tesa film was obtained from TESA SE, Hamburg, Germany. The OVA 
specific ELISA kit was purchased from USCN life science Inc. (Hölzel Diganostik, 
Germany). All other solvents and chemicals used were of the highest grade 
commercially available. Deionized water (Milli Q Plus system, Millipore, Bedford, 
MA, USA) was used throughout the investigation. 
4.3.2. Pig ear skin 
Ears from freshly slaughtered pigs were removed before scalding. The ears were 
washed with water, blotted dry and the hairs were shortened with scissors. The 
ears were stored at 4-8 °C for a maximum period of 3 days. 
4.3.3. Mice 
C57BL/6 (H-2b) female mice (6-8 weeks old) were purchased from Harlan 
(Germany). OVA-TCR transgenic mice C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I) 
and C57BL/6-Tg(TcraTcrb)425Cbn (OT-II) were bred at the animal facility of the 
Helmholtz Centre for Infection Research (Germany) under specific pathogen-free 
conditions. 
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4.3.4. Nanoparticles preparation  
IMSG NPs 
 
IMSG NPs were prepared from inverse micelles of lecithin in chloroform by freeze-
drying. To this end, 440 mg of lecithin and 60 mg span 80 were dissolved in 1.4 ml 
of chloroform in a glass vial using continuous stirring. The aqueous phase of 0.15 
ml containing OVA (6 mg) and trehalose (6 mg) was added and the mixture was 
sonicated for 20 s at 8 W. The inverse micelle suspension which formed was flash-
frozen in liquid N2 and subsequently freeze dried for 48 h to remove the organic 
solvent and water. The resulting IMSG particles were dispersed in medium chain 
triglycerides (MCT). Antigen/adjuvant (OVA + c-di-AMP) co-encapsulated IMSG 
NPs were prepared by adding 0.9 mg of c-di-AMP to the aqueous phase for TF 
route. For ID route, co-encapsulated NPs were prepared in similar manner as 
described above with different amount of OVA (2 mg) and c-di-AMP (1.5 mg) 
added to aqueous phase. FITC labelled IMSG NPs were prepared by replacing 
OVA with FITC-OVA.  
 
Chitosan-PLGA NPs 
 
OVA-loaded Chit-PLGA NPs were prepared by a modified double emulsion 
method [12]. Briefly, 50 mg of PLGA were dissolved in 2 ml of ethyl acetate at 
room temperature. Then 400 µl of (1.875% wt/V) OVA solution in PBS was added 
to form primary water-in-oil (w/o) emulsion. After sonicating at 6 W for 15 s, 4 ml of 
2% (wt/V) PVA and Protasan® UP CL113 (0.2% wt/V) solution was added to the 
primary emulsion which was again sonicated at 8 W for 20 s. Water was added 
drop-wise to the resulting w/o/w emulsion under constant stirring to allow diffusion 
and evaporation of the organic solvent. The particles were collected by 
centrifugation at 10,000 × g for 15 min, washed once with distilled water to remove 
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excess surfactant and free drug and freeze dried using trehalose (0.2% wt/V) as 
cryoprotectant. FITC labelled Chit-PLGA NPs were prepared by replacing OVA 
with OVA-FITC. 
4.3.5. Nanoparticle characterization 
Size and ζ-potential of the NPs were analyzed by photon correlation spectroscopy 
(PCS) using a Nano-ZS (Malvern Instruments, Malvern, UK). The morphology of 
the NPs was characterized using transmission electron microscopy (TEM) (Tecnai 
12 G2, FEI Company Hillsboro, Oregon, USA). For TEM, prior to scanning diluted 
suspensions of freeze dried NPs in cyclohexane were taken and mounted on a 
copper grid and subsequently dried at room temperature. Then, samples were 
negatively stained with a 1% solution of phosphor-tungstic acid and further 
examined.  
4.3.6. Integrity and Activity of OVA 
The integrity of OVA was determined by SDS PAGE analysis. For IMSG NPs, 
briefly, OVA was extracted from freeze-fried NPs and oily dispersion with 
phosphate buffer (pH 7) under continuous stirring at 100 rpm. The dispersion was 
then centrifuged for 5 min at 5000 g to sediment the surfactant. A dose of 1 µg of 
OVA was loaded onto a 12% (wt/V) polyacrylamide gel under reducing conditions 
[12]. Detection of protein was performed by staining with colloidal Coomassie blue 
(Fermentas, St. Leonrot, Germany). 
To determine the activity of OVA encapsulated in NPs, OVA was extracted as 
described above. The active OVA fraction was quantified using an ELISA assay 
which was performed according to the instructions provided by the manufacturer. 
The ELISA was calibrated using standards provided by the manufacturer in the 
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range of 0.156 – 10 ng/ml (lower limit of detection, LLOD = 0.053 ng/ml). 
Supernatant obtained from blank NPs were used as negative control. 
4.3.7. Evaluation and quantification of follicular uptake on excised pig ears: 
Influence of encapsulating OVA into particles 
Incubation sites of 1.767 cm² were marked on the outer auricle of the pig ears with 
a permanent marker. A dose of 20 µl of either an aqueous solution of FITC-OVA, 
an aqueous dispersion of FITC-OVA in Chit-PLGA NPs and FITC-OVA in IMSG 
NPs (11.5 µg OVA/cm²) were applied and massaged manually with a gloved 
forefinger for 3 min. The ears were incubated for 1 h at 32°C under non-occlusive 
conditions. 
After the incubation the skin surface was cleaned from remaining formulation by 
removing 10 tape strips (Tesa kristallklar, Tesa SE, Germany). A roller was used 
to enhance the contact between tape strip and skin surface [53]. Subsequently, 2 
cyanoacrylate biopsies were performed to collect the amount of OVA penetrated 
into the hair follicles. The cyanoacrylate biopsies were extracted in acetonitrile: 0.1 
N NaOH (50:50) for 3 h on a horizontal shaker and the fluorescence intensity of all 
samples was measured using a Tecan platereader (Excitation 490 nm, Emission 
525 nm). The amount of FITC-OVA extracted from the cyanoacrylate biopsies was 
calculated with the help of standards prepared from FITC-OVA / FITC-OVA in 
Chit-PLGA NPs/ FITC-OVA in IMSG NPs dissolved in acetonitrile: 0.1 N NaOH 
(50:50) in the range of 0.1-10 µg/ml. The results for the NPs were expressed 
relatively to FITC-OVA solution.  
Blank samples were taken from an incubation site of the same pig ear, where 
double distilled water/ medium chain triglycerides was applied instead of NPs. The 
blank values were subtracted from the fluorescence intensity of the samples. 
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4.3.8. Adoptive transfer model of TCR transgenic CD4 T cells to characterize 
OVA specific proliferation 
For the adoptive transfer experiment naïve CD4+ T-cells (CD4+ CD62Lhi CD44lo 
CD25-) were isolated from pooled lymph nodes and spleens of OTII x Thy1.1 
transgenic mice using an ARIA II sorter (purity ≥98%). These cells not only 
express the OVA-peptide AA323-339 specific T cell receptor (TCR) but also the 
congenic marker Thy1.1 (CD90.1). The congenic marker CD90.1, which slightly 
differs in structure but not in function from the wild type receptor Thy1.2 (CD90.2), 
allows the identification of the transferred cells ex vivo using non-cross-reactive 
monoclonal antibodies. After the sorting cells were labeled with CFSE, in order to 
track their proliferative capacity, and finally injected intravenously (1.5 x 106 per 
mouse) one day prior to immunization into C57BL/6 mice.  
Immunization was carried out on the flank part of the mice by either subcutaneous 
(s.c.) or transfollicular (TF) route. Flanks were shaved (under anesthesia) 2 d 
before immunization. Shaved areas were carefully inspected for cuts or skin 
irritation in which case these mice were excluded from the experiment. Animals 
were assorted to the following treatment groups (3 animals per group): (1) 
negative control, received blank IMSG NPs via TF route; (2) received 25 µg LPS-
free OVA in Chit-PLGA NPs + 5 µg c-di-AMP as adjuvant via TF application; (3) 
received 25 µg LPS-free OVA in IMSG NPs via TF application, (4) received 25 µg 
LPS-free OVA + 5 µg c-di AMP / 20 µl loaded in IMSG NPs via TF route; (5) 
positive control, received 25 µg LPS-free OVA + 5 µg c-di AMP / 20 µl loaded in 
IMSG NPs via s.c. route. After another 4 days animals were sacrificed and spleens 
and draining lymph nodes (illiac and axillary LNs pooled) were isolated separately 
for each animal. Cells were stained for live/dead, CD3+, CD4+ and Thy1.1+ and 
analyzed using a LSRII flow cytometer. The proliferative capacity of (CD3+ CD4+ 
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Thy1.1+ was analyzed using the BD FACSDiva™ Software (BD Biosciences, 
USA). 
4.3.9. Immunization protocols 
Female C57BL/6 mice (n = 5) were immunized on day 0, 14 and 28 with different 
vaccine formulations encompassing either OVA protein alone or admixed with c-di-
AMP in an aqueous solution or encapsulated in IMSG NPs via IN, ID or TF route. 
Antigen dose and application volumes were adjusted to the specific administration 
route, as depicted in Table 1. 
TF vaccination was carried on the flank part of the mice. In brief, 2 days prior the 
immunization mice were anesthetized and hair was removed using clippers and a 
depilatory cream. Depilated areas were washed and carefully inspected for cuts or 
skin irritation in which case these mice were excluded from the experiment. 
4.3.10. Sample collection 
Blood samples from immunized mice were taken from the retro-orbital complex on 
day −1, 13, 27 and 48. To separate sera, blood samples were incubated first for 1 
h at 37°C followed by 30 min incubation at 4°C. Subsequently, samples were 
centrifuged at 3000 × g for 10 min and sera were stored at −20°C until further 
processing. On day 48, mice were sacrificed, lymph nodes and spleens were 
collected and single cell suspensions were obtained by mechanically 
homogenization of the organs using a sieve (100 µm). Cell suspensions were 
generated and analysed for the presence of antigen-specific cells, as previously 
described [95]. 
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Table 1.  
Immunization groups  
Group Route Dose (OVA ± c-di-AMP) 
Blank NPs + c-di-AMP I.N. Equivalent to OVA-loaded NPs 
OVA I.N. 10 µg/20 µl 
OVA + c-di-AMP I.N. 10 µg + 7.5 µg/20 µl 
OVA NPs I.N. 10 µg/20 µl 
OVA + c-di-AMP NPs I.N. 10 µg + 7.5 µg/20 µl 
Blank NPs + c-di-AMP I.D. Equivalent to OVA-loaded NPs 
OVA I.D. 10 µg/20 µl 
OVA + c-di-AMP I.D. 10 µg + 7.5 µg/20 µl 
OVA NPs I.D. 10 µg/ 20 µl 
OVA + c-di-AMP NPs I.D. 10 µg + 7.5 µg/20 µl 
Blank NPs + c-di-AMP T.F. Equivalent to OVA-loaded NPs 
OVA T.F. 200 µg/60 µl 
OVA + c-di-AMP T.F. 200 µg + 20 µg/60 µl 
OVA NPs T.F. 200 µg/60 µl 
OVA + c-di-AMP NPs T.F. 200 µg + 20 µg/60 µl 
IN: intranasal, ID: intradermal, TF: transfollicular, OVA: ovalbumin, NPs: nanoparticles 
 
4.3.11. Detection of antigen-specific IgG and IgG subtypes 
OVA-specific antibodies in sera of individual animals were determined by ELISA 
using microtiter plates coated with 100 µl/well of the antigen (2 µg/ml in 0.05 M 
carbonate buffer, pH 9.6), as previously described [95]. Briefly, Antigen coated 
microtiter plates wer incubated overnight incubation at 4 °C, plates were then 
incubated with 3% bovine serum albumin (BSA) in PBS for 1 h at 37 °C in order to 
block unspecific binding sites. Before serial 2-fold dilutions of sera in 3% BSA/PBS 
were added (100µl/well) plates were washed six times with 1% BSA/PBS/0.05% 
Tween 20. After 1 h of incubation at 37 °C plates were washed six times with 1% 
BSA/PBS/0.05% Tween 20 and the secondary antibody was added: biotinylated γ 
chain-specific goat anti-mouse IgG, IgG1 and IgG2c (Sigma, USA), respectively. 
Subsequently, samples were again incubated at 37 °C for 1 h [see above]. 
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Afterwards, plates were washed six times peroxidase-conjugated streptavidine 
(BD Pharmingen, USA) was added to each well (100 µl/well) and plates were 
incubated for 1 h at RT. Finally, after another six washes, reactions were 
developed using 100 µl of ABTS [2, 20-azino-bis(3- ethylbenzthiazoline-6-sulfonic 
acid)] in 0.1 M citrate-phosphate buffer (pH 4.35) containing 0.01% H2O2. Endpoint 
titres are expressed as absolute values of the last sample dilution that after a 15 
and 30 min incubation gave a 2 times higher optical density at 405 nm compared 
to the negative control values. 
4.3.12. Evaluation of cellular proliferation and cytokine profiles 
The proliferative activity of immune cells derived from spleen and lymph nodes of 
immunized mice was measured as previously described [95]. Briefly, Erythrocytes 
were lysed from immune cells by incubating them for 1 min with ammonium 
chloride (ACK) buffer. Lysis was stopped by adding complete medium (RPMI 
supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 μg/ml 
streptomycin). Subsequently, cell suspensions were adjusted to 5 × 106 cells/ml 
and seeded in quadruplicates at 100 µl/well in flat-bottomed 96-well microtiter 
plates (Nunc, Roskilde, Denmark). Plates were incubated for 4 days in the 
presence of different concentrations of EndoGrade® Ovalbumin (Hyglos, 
Germany), 5 µg/ml Concanavalin A or medium. During the final 18 h of culture, 
cells were incubated with 1 µCi/well of (3H)thymidine (Amersham International, 
Freiburg, Germany). Finally, cells were harvested on paper filters (Filtermat A; 
Wallac, Freiburg, Germany) by using a cell harvester (Inotech, Wohlen, 
Switzerland) and the relative amount of proliferating cells was determined by 
measuring the beta radiation of (3H)thymidine incorporated into the DNA of the 
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cells Wallac 1450 ß-scintillation counter Micro-Trilux). The obtained results are 
expressed as counts per minute (cpm) and stimulation index (SI), respectively. 
 To quantify the cytokines and chemokines secreted by antigen-specific immune 
cells, lymph node derived cells and splenocytes were adjusted to a concentration 
of 5 × 106 cells/ml, seeded in quadruplicates at 100 µl/well in flat-bottomed 96-well 
microtiter plates (Nunc, Roskilde, Denmark) and re-stimulated in vitro for 96 h with 
different concentrations of EndoGrade® OVA (Hyglos, Germany). Afterwards, 
supernatants were collected and stored at −80°C until processing. Cytokine 
amounts (IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, TNFα and IFN) were 
determined using the Mouse Th1/Th2 FlowCytomix Multiplex cytokine array, 
according to the manufacturer’s instructions (eBioscience, Bender MedSytems®, 
USA).  
4.3.13. Multifunctional T cells 
To evaluate the capacity of different vaccine formulations to stimulate OVA 
specific multifunctional T cells, splenocytes from immunized mice were isolated 
and their capacity to produce different cytokines was evaluated by flow cytometry. 
Splenocytes (2 x 107 cells per well) of immunized mice were incubated (37 °C, 5 % 
CO2) in 2 ml RPMI containing OVA protein [1µg/ml]. After 16-20 hours 5 µg/ml 
BrefeldinA and 6 µg/ml Monensin (Sigma-Chemie, Germany) were added and 
cells were incubated for additional 6 hours. Subsequently, cells were stained for 
dead cells (Fixable Dead Cell Stain, Invitrogen, USA) and surface markers (CD3 
and CD8, BD, USA; CD4, eBioscience, Germany). Then, cells were fixed with 2 
%PFA, permealized for 45-60 min with 0.5 % BSA and 0.5 % Saponin in PBS and 
stained for intracellular cytokines (IL-2 and IFN, BD, USA; TNFα, IL-17 and IL-4, 
eBioscience, Germany). Finally, cells were resuspended in PBS and light emission 
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measured using BD LSRII. After spectral overlap compensation with the BD FACS 
Diva Software, the data were analyzed using FlowJo (Tree Star, USA) 
4.3.14. Statistical analysis 
Statistical significance of the observed differences was analysed using the Graph 
Pad Prism 5 software for Windows (Version 5.04) by the one-way ANOVA test. 
Differences were considered significant at p<0.05 (*), p<0.01 (**), p<0.001 (***) 
and p<0.0001 (****), respectively.  
 
 
4.4. Results 
4.4.1. Characterization of OVA-loaded IMSG NPs 
The characteristics of the NPs are summarized in Table 2. The TEM image in 
Fig.1 shows smooth, spherical particles. The mean size of OVA-loaded IMSG NPs 
(+/- c-di-AMP) for all three routes was approximately 300-350 nm with a mono-
disperse size distribution (PDI < 0.2). Adjuvant incorporation into NPs does not 
change the particle characteristics in terms of size and PDI.  
 
Table 2.  
Physico-chemical characterization of the optimized IMSG NPs 
S.no. NPs Route Size (nm) PDI 
1 OVA loaded IMSG NPs I.D. and I.N. 312.2 ± 14.6 0.146 ± 0.02 
2 OVA + c-di-AMP IMSG NPs I.D. and I.N. 301.1 ± 14.2 0.146 ± 0.01 
3 OVA loaded IMSG NPs T.F. 317.4 ± 22.1 0.125 ± 0.04 
4 OVA + c-di-AMP IMSG NPs T.F. 323.6 ± 9.4 0.132 ± 0.03 
Values represent mean ± standard deviation of n = 6 independently prepared batches. I.D.- intra-
dermal, I.N.: intra-nasal, T.F.: transfollicular application of NPs. PDI: poly-dispersity index 
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Fig. 1. TEM image of OVA loaded IMSG NPs 
 
4.4.2. Integrity and bio-availability of OVA are not affected by IMSG NP 
generation process 
To investigate the formation of fragments or aggregates of OVA during NP 
preparation as well as dispersion in an oily solution, a SDS PAGE was performed. 
No difference in the migration pattern of OVA extracted from IMSG NPs compared 
to OVA in aqueous solution was observed (Fig. 2). In addition, OVA integrity is not 
affected by the NP generation process since no degradation fragments were 
observed when OVA was extracted from NPs (lanes 5 and 8, Fig. 2). The smear 
observed after coomassie staining resulted from the lecithin component as 
evidenced by lanes 3 and 6. 
To further validate the proper integrity of the OVA molecules following NP 
formation, ELISA were performed using the OVA which had been extracted from 
the NPs. By relating the total amount of protein in the NP sample, the bio-
availability of the encapsulated OVA was determined as 85 ± 5 % in OVA-loaded 
IMSG NPs. 
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Fig. 2. Integrity of OVA extracted from NPs by water and analysed by SDS PAGE, Lane1: 
Molecular weight Marker, Lane2: OVA in solution, Lane3: Lecithin + water, Lane4: Physical 
mixture (OVA + lecithin + water), Lane5: OVA NPs in water, Lane6: Lecithin + oil + water, Lane7: 
Physical mixture (OVA + lecithin + oil + water), Lane 8: OVA NPs in oil + water 
 
4.4.3. Follicular uptake of Nanoparticles  
Fig. 3A shows representative images illustrating the distribution of fluorescently 
labeled IMSG NPs on the skin surface and in the hair follicle after application to 
excised pig ears. NPs accumulate in the follicle openings, cover the hair and 
invade the follicular duct. The magnitude of NPs invaded was evaluated by 
quantifying the fluorescence measured in cyanoacrylate biopsy extracts (Fig. 3B). 
Thus, encapsulation of OVA into IMSG NPs significantly enhanced (p<0.001) 
follicular delivery of OVA by a factor of 4.38 ± 0.81 compared to OVA solution and 
1.89 ± 0.35 compared to OVA-loaded Chit-PLGAs.  
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Fig. 3. A) Distribution of fluorescently labelled NPs in hair follicles after application to excised pig 
ears. (LSM 510 Meta, Carl Zeiss GmbH, Jena Germany; excitation wavelength 458 nm), 
Transversal cryo section (thickness 12 µm); overlay of fluorescence and transmission light images: 
NPs are visible on the skin surface and inside the follicle. (B) Quantitative extraction of tapes, 
superglue biopsy and application device + skin rest allows to quantify the amount of particles that is 
deposited on the “skin surface” (tapes), inside the “hair follicle” (superglue biopsy) and “others” 
(application device + skin rest) respectively. Follicular uptake of FITC-labelled OVA encapsulated 
in IMSG NPs relative to FITC-OVA solution and FITC-OVA in Chit- PLGA NP (n = 6, mean ± SD; 
differences were considered significant whenever (* p<0.05, *** p<0.001) compared to OVA-FITC 
solution. 
 
4.4.4. IMSG NPs efficiently deliver OVA to immune cells via TF route 
In order to verify the overall feasibility of transfollicular delivery of OVA using IMSG 
NPs as well as to evaluate their superiority to OVA-loaded Chit-PLGA NPs, an 
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adoptive transfer model was established. Proliferation of adoptively transferred 
OVA-specific CD4+ T (OT-II) cells was measured by CFSE dilution.  
 
Fig. 4. The percentage of divided transferred cells in the draining lymph nodes (a) and the spleen 
(b) for each experimental group is shown. The three animals of each group were analyzed 
separately. While no proliferation was observed in the negative control (Gr. 1.), full proliferation of 
the transferred cells was observed in animals of the positive control group (Gr. 5.). No differences 
were seen in the proliferation of lymph nodes cells between different tested groups (Gr. 2. (OVA 
loaded Chit-PLGA NPs + c-di AMP) and Gr. 3. (OVA-loaded IMSG NPs immunized transfollicularly) 
& Gr. 4. (OVA + c-di AMP loaded IMSG NPs immunized transfollicularly)). However, spleen cells 
showed significant differences in the proliferation between Gr. 4 and Gr. 2. Differences were 
considered significant at p<0.05 (*). 
 
 
As shown in Fig. 4, all tested vaccine formulations efficiently stimulated 
proliferation of OT-II cells following TF vaccination except blank NPs. No 
differences in the proliferative capacity of LN derived cells were detected between 
groups immunized by TF route (Fig. 4A). In contrast, significant differences (p< 
0.05) were observed when analyzing the proliferative capacity of spleen derived 
OT-II cells from mice immunized with OVA + c-di-AMP IMSG NPs in comparison 
to OVA Chit-PLGA NPs + c-di AMP. Thus, OVA + c-di AMP loaded IMSG NPs 
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seems to be more efficient in delivering OVA into hair follicles compared to OVA 
loaded Chit-PLGA NPs + c-di AMP (Fig. 4B). 
 
4.4.5. Adjuvanted IMSG NPs stimulate efficient humoral immune responses 
following ID immunization  
Vaccine formulations were well tolerated, since no obvious signs of acute toxicity 
(e.g. weight loss, reduced mobility, hair straightened up) were observed following 
vaccination. The highest OVA-specific IgG titre was stimulated using OVA + c-di-
AMP co-encapsulated IMSG NPs (Fig. 5A). The differences were significant as 
compared to all tested formulations (p<0.001). Interestingly, high titres were 
observed even after a single boost, whereas for all other formulations a second 
boost was needed in order to stimulate antibody production (Fig. 5B). 
Interestingly, OVA-loaded IMSG NPs generated similar IgG titres  compared to 
OVA protein co-administered with c-di-AMP indicating the beneficial effect of 
IMSG NPs. OVA protein alone generated lowest IgG titres when injected ID. 
As expected, incorporation of c-di-AMP as adjuvant resulted in the stimulation of 
mixed Th1/Th2 responses, as indicated by increased levels of IgG2c antibodies in 
sera of immunized mice (Fig. 5C). In contrast, OVA protein alone or encapsulated 
in IMSG NPs stimulated predominant production of IgG1, indicating a Th2 biased 
response. However, the strongest IgG2c titres (p<0.05) were stimulated in mice 
receiving OVA + c-di-AMP co-encapsulated in IMSG NPs (Fig. 5C). 
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Fig. 5. Systemic humoral immune responses stimulated in C57BL/6 mice (n = 5) after three 
immunizations with different OVA containing formulations via ID route. (A) OVA-specific IgG titres 
in sera of mice 20 d after the last immunization. (B) Kinetics of OVA-specific IgG production in sera 
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of immunized mice on day 0, 13, 27 and 48.  (C) OVA-specific IgG subclasses in sera of 
immunized mice. Results are expressed as the last dilution giving the double value (OD450 nm) of 
the background value (negative control). Standard error of mean (SEM) is indicated by vertical 
lines. Differences were considered significant at p<0.05 (*), p<0.001 (***) and p<0.0001 (****), 
respectively 
 
 
4.4.6. Adjuvanted IMSG NPs stimulate efficient cellular immune responses 
following ID immunization 
ID immunization of mice using OVA + c-di-AMP co-encapsulated in IMSG NPs 
stimulated the strongest cellular response, whereas OVA protein alone or 
encapsulated in IMSG NPs was less efficient (Fig. 6A). The absolute numbers of 
proliferating cells were higher at local level with respect to systemic responses.  To 
further characterize the stimulated responses we analysed the cytokine secretion 
profiles of splenocytes and LN derived cells from vaccinated mice by cytometric 
bead arrays (Fig. 6B). The strongest cytokine production was stimulated in mice 
immunized with OVA co-administered with c-di-AMP, followed by those receiving 
OVA + c-di-AMP co-encapsulated IMSG NPs (Fig. 6B).  
Only vaccine formulations including c-di-AMP stimulated strong production of 
IFNVA alone or OVA encapsulated in IMSG NPs stimulated predominantly IL-
13, followed by IL-5 and IL-10 (Fig. 6B). Only mice receiving OVA + c-di-AMP co-
encapsulated in IMSG NPs showed significantly increased levels of TNF-α, IL-17 
and IL-6. No significant differences were observed in the cytokine profiles of 
groups receiving OVA protein or OVA loaded IMSG NPs, besides from the fact 
that the absolute numbers of different cytokines (IL-5, Il-13 and INF) being higher 
in mice receiving OVA loaded IMSG NPs. In line with the obtained IgG subclass 
patterns, vaccine formulations containing c-di-AMP stimulated a mixed Th1/Th2 
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response, whereas those without adjuvant promoted a Th2-dominated response 
(Fig. 6B). 
Recent findings support the assumption that vaccine efficacy not only depends on 
the strength but also, to a large extent, on the quality of the stimulated T cell 
response. In this regard, stimulation of multifunctional T cells which possess a 
broader functional spectrum results in enhanced protective immunity, as compared 
to mono-functional cells [98].  
Therefore, we investigated the quality of the T cell responses stimulated by IMSG 
NPs. Immunization with OVA encapsulated IMSG NPs already increases the 
proportion of OVA-specific bi- (IFN+/TNFα+, IFN+/IL-2+) and tri-functional 
(IFN+/TNFα/IL-2+) CD4+ T cells, as compared to OVA alone. This effect was 
further strengthened using OVA + c-di-AMP co-encapsulated IMSG NPs (Fig. 6C). 
A similar pattern was observed following vaccination with OVA protein add-mixed 
with c-di-AMP. Nevertheless, the highest number of IFN producing CD4+ T cells 
was stimulated by combining IMSG NPs with c-di-AMP (Fig. 6C). None of the 
vaccine formulations was able to stimulate antigen-specific CD8+ T cells. 
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Fig. 6. Cellular responses stimulated following ID immunization. Splenocytes (upper panel) and LN 
cells (lower panel) from vaccinated animals were restimulated with different concentrations of OVA 
for 96 h. (A) Cellular proliferation was assessed by determination of the [
3
H] thymidine incorporated 
into the DNA of replicating cells. Results are averages of quadruplicates and expressed as 
stimulation index (SI). (B) Cytokine profiles stimulated by the different vaccine formulations were 
evaluated by cytometric bead array. Results are expressed in pg/ml. (C) Quality of the T cell 
responses stimulated following vaccination via ID route. Cells were collected at day 20 after the last 
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immunization and subsequently incubated for 24 h in the presence and absence, respectively, of 
OVA. Results are expressed as difference between re- and non-restimulated % of all CD4+ cells 
expressing IFN. Living cells were gated for CD3+ CD4+ double positive cells. These 
subpopulation was further divided into monofunctional expressing only IFN, bifunctional 
expressing two cytokines (IFN / IL-2 or IFN / TNF) and trifunctional expressing IFN, IL-2 
and TNF Pie charts represent the proportion of tri- (black), bi- (dark gray) and mono-functional 
(light gray) cells. The differences were considered significant compared to OVA alone at p<0.05 (*), 
p<0.01 (**) and p<0.0001 (****), respectively. 
 
4.4.7. Adjuvanted IMSG NPs fail to stimulate efficient humoral immune 
responses following IN immunization 
Serum anti-OVA IgG antibody titres obtained after IN vaccination with OVA and 
OVA-loaded NPs with or without introduction of c-di-AMP as adjuvant are shown in 
Fig. 7A. OVA co-administered with c-di-AMP stimulated the highest OVA-specific 
IgG titres as compared to all tested formulations (p<0.001). Surprisingly, in 
contrast to ID vaccination, immunization of mice with OVA-encapsulated NPs and 
OVA + c-di-AMP co-encapsulated NPs via the IN route stimulated only very low 
IgG titres. Furthermore, mice need to receive three immunizations in order to 
stimulate efficient antibody titres (Fig. 7B), suggesting problems related to NPs 
delivery across the mucosal barrier. As described for ID immunization, co-
administration of c-di-AMP results in a significantly increased production of IgG2c 
compared to all tested formulations (p<0.01, Fig. 7C). 
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Fig. 7. Systemic humoral immune responses stimulated in C57BL/6 mice (n = 5) after three 
immunizations with different OVA containing formulations via IN route. (A) OVA-specific IgG titres 
in sera of mice 20 d after the last immunization. (B) Kinetics of OVA-specific IgG production in sera 
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of immunized mice on day 0, 13, 27 and 48.  (C) OVA-specific IgG subclasses in sera of 
immunized mice. Results are expressed as the last dilution giving the double value (OD450 nm) of 
the background value (negative control). Standard error of mean (SEM) is indicated by vertical 
lines. Differences were considered significant at p<0.05 (*) and p<0.001 (***), respectively. 
 
4.4.8. Adjuvanted IMSG NPs fail to stimulate efficient cellular immune 
responses following IN immunization 
In contrast to the ID vaccination strategy, IN immunization of mice with IMSG NPs 
did not result in the stimulation of strong cellular responses. Thus, only marginal 
proliferation was observed of re-stimulated splenocytes and LN cells derived from 
mice vaccinated with OVA + c-di-AMP co-encapsulated IMSG NPs (Fig. 8A). As 
expected, strong proliferative and cytokine responses were obtained when cells 
from control mice receiving OVA co-administered with c-di-AMP by IN route were 
tested (Fig. 8A and 8B). Similarly to the profiles stimulated by ID immunization, 
INFwas the dominant cytokine induced by adjuvantation with c-di-AMP. 
However, IN vaccination with OVA co-administered with c-di-AMP also induced 
strong IL-17 and IL-13 production. Interestingly, IL-5 production was considerably 
decreased with respect to what observed after ID immunization (Fig. 8B). No or 
only very low amounts of cytokines were detected in mice receiving OVA loaded 
IMSG NPs.  
Similar to what observed after immunization via the ID route, none of the vaccine 
formulations was able to stimulate antigen-specific CD8+ T cells when applied by 
IN route. However, CD4+ cellular responses were slightly increased in mice 
vaccinated with OVA + c-di-AMP co-encapsulated IMSG NPs (Fig. 8C). As shown 
for ID immunization, incorporation of c-di-AMP results in higher numbers of OVA-
specific bi- (IFN+/TNFα+, IFN+/IL-2+) and tri-functional (IFN+/TNFα/IL-2+) 
CD4+ T cells, as compared to values in animals receiving OVA alone and OVA 
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encapsulated IMSG NPs (Fig. 8C). Control mice receiving OVA co-administered 
with c-di-AMP showed the highest number of IFN producing CD4+ T cells and 
slightly better proportion of bi- and tri-functional cells (Fig. 8C). 
 
Fig. 8. Cellular responses stimulated following IN immunization. Splenocytes (upper panel) and LN 
cells (lower panel) from vaccinated animals were restimulated with different concentrations of OVA 
for 96 h. (A) Cellular proliferation was assessed by determination of the [
3
H] thymidine incorporated 
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into the DNA of replicating cells. Results are averages of quadruplicates and expressed as 
stimulation index (SI). (B) Cytokine profiles stimulated by the different vaccine formulations were 
evaluated by cytometric bead array. Results are expressed in pg/ml. (C) Quality of the T cell 
responses stimulated following vaccination via IN route. Cells were collected at day 20 after the last 
immunization and subsequently incubated for 24 h in the presence and absence, respectively, of 
OVA. Results are expressed as difference between re- and non-restimulated % of all CD4+ cells 
expressing IFN. Living cells were gated for CD3+ CD4+ double positive cells. These 
subpopulation was further divided into monofunctional expressing only IFN, bifunctional 
expressing two cytokines (IFN / IL-2 or IFN / TNF) and trifunctional expressing IFN, IL-2 
and TNF Pie charts represent the proportion of tri- (black), bi- (dark gray) and mono-functional 
(light gray) cells. The differences were considered significant compared to OVA alone at p<0.01 
(**), p<0.001 (***), and p<0.0001 (****), respectively. 
 
4.4.9. Adjuvanted IMSG NPs stimulate efficient humoral immune responses 
following TF vaccination 
When mice were vaccinated by TF route, the highest serum anti-OVA IgG titres 
(p<0.001) were observed in mice receiving OVA + c-di-AMP co-encapsulated 
IMSG NPs (Fig. 9A). Differences in titres were significant already after the 1st 
boost (p<0.001). However, also IMSG NPs loaded with OVA alone stimulated 
significantly stronger IgG production than OVA alone or co-administered with c-di-
AMP. This shows the beneficial effect of antigen encapsulation within IMSG NPs 
for TF vaccination. In contrast, similar IgG titres were stimulated when OVA was 
applied via ID route encapsulated in IMSG NPs or co-administered with c-di-AMP 
(Fig. 9A). However, while ID immunization with OVA + c-di-AMP co-encapsulated 
IMSG NPs stimulated strong humoral responses already after a single boost, TF 
vaccination needed a 2nd boost in order to stimulate efficient OVA-specific IgG 
titres (Fig. 9B). As expected, the overall IgG titres stimulated after immunization 
via TF route were lower than those obtained after ID vaccination. Unlike the IgG 
subclass pattern observed after ID and IN vaccination, TF immunization of mice 
stimulated only poor IgG2c responses (Fig.9C). 
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Fig. 9. Systemic humoral immune responses stimulated in C57BL/6 mice after three vaccinations 
with different OVA containing formulations TF. (A) Total OVA specific IgG titres in sera after 
immunization (n = 5). (B) Kinetics analysis of OVA specific IgG titres in sera of immunized mice on 
day 0, 14, 28 with (n = 5).  (C) Analysis of OVA specific IgG subclasses in sera of immunized mice 
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(n = 5). Differences in outcome between different tested groups were assessed using One way 
ANOVA. Differences were considered significant at p<0.05 (*), p<0.001 (***) and p<0.0001 (****), 
respectively. 
 
4.4.10. Adjuvanted IMSG NPs stimulate efficient cellular immune responses 
following TF vaccination 
The strongest cellular response at local and systemic level was stimulated by OVA 
+ c-di-AMP co-encapsulated IMSG NPs, as indicated by strong proliferative 
responses (Fig. 10A upper panel; p<0.0001). However, also NPs encapsulated 
OVA and OVA co-administered with c-di-AMP stimulated significantly increased 
(p<0.01) proliferative responses of LN derived cells, as compared to cells derived 
from OVA and Blank NPs immunized mice (Fig. 10A, lower panel).  
When analysing the cytokine profiles stimulated following TF vaccination, it turned 
out that application of IMSG NPs on intact skin stimulated similar profiles, as 
compared to IN immunization, namely, high titres of IFN, IL-13 and IL-17 (Fig. 
10B). However, while at local level IFN was strongest induced cytokine followed 
by IL-13 and IL-17, at systemic level this pattern was only observed after 
restimulation of splenocytes from mice receiving OVA + c-di-AMP co-encapsulated 
IMSG NPs (Fig. 10B). Splenocytes from mice receiving all other formulations 
produce predominantly IL-13, followed by IFNand IL-17. Interestingly, while OVA 
encapsulated IMSG NPs were less efficient at stimulating cellular responses 
compared to OVA + c-di-AMP co-encapsulated IMSG NPs when administered by 
IN or ID route, only small differences were observed after TF vaccination (Fig. 
10B). In agreement with the stimulated IgG subclasses observed after TF 
immunization, the observed cytokine profiles indicate a Th2-dominated immune 
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response. Only OVA + c-di-AMP co-encapsulated IMSG NPs seem to be able to 
stimulate a mixed Th1/Th2 response.  
Compared to IN or ID vaccination, TF immunization stimulated only weak induction 
of multifunctional CD4+ T cells (Fig. 10C). Furthermore, immunization with either 
OVA alone, OVA co-administered with c-di-AMP or OVA encapsulated IMSG NPs 
resulted in the generation of mainly (~70%) mono-functional (IFN+ CD4+ T cells, 
followed by bi- (IFN+/TNFα+, IFN+/IL-2+, ~23%) and tri-functional 
(IFN+/TNFα/IL-2+, ~6%) CD4+ T cells (Fig. 10C). No significant differences were 
observed between these groups. In contrast, mice immunized with OVA + c-di-
AMP co-encapsulated IMSG NPs showed an improved quality of CD4+ responses, 
as indicated by increased proportions of bi- and tri-functional CD4+ cells (Fig. 
10C). As shown for IN and ID immunization, incorporation of c-di-AMP results in 
increased quality of the stimulated cellular responses after TF immunization (Fig. 
10C). However, no OVA-specific CD8+ cells were detected. 
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Fig. 10. Cellular responses stimulated following TF immunization. Splenocytes (upper panel) and 
LN cells (lower panel) from vaccinated animals were restimulated with different concentrations of 
OVA for 96 h. (A) Cellular proliferation was assessed by determination of the [
3
H] thymidine 
incorporated into the DNA of replicating cells. Results are averages of quadruplicates and 
expressed as stimulation index (SI). (B) Cytokine profiles stimulated by the different vaccine 
formulations were evaluated by cytometric bead array. Results are expressed in pg/ml. (C) Quality 
of the T cell responses stimulated following vaccination via TF route. Cells were collected at day 20 
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after the last immunization and subsequently incubated for 24 h in the presence and absence, 
respectively, of OVA. Results are expressed as difference between re- and non-restimulated % of 
all CD4+ cells expressing IFN. Living cells were gated for CD3+ CD4+ double positive cells. 
These subpopulation was further divided into monofunctional expressing only IFN, bifunctional 
expressing two cytokines (IFN / IL-2 or IFN / TNF) and trifunctional expressing IFN, IL-2 
and TNF Pie charts represent the proportion of tri- (black), bi- (dark gray) and mono-functional 
(light gray) cells. The differences were considered significant compared to OVA alone at p<0.01 
(**) and p<0.0001 (****), respectively. 
 
 
4.5. Discussion 
Micro- and nanoparticle based delivery systems offer unique possibilities to create 
safe and effective vaccines [122]. However, the route of vaccination is also an 
important parameter to define the immune response triggered by particulate 
carriers. This is not only due to differences in physic-chemical properties (e.g. size, 
surface charge) or the carrier, but also due to targeted antigen delivery to APCs 
located at the inductive site [123]. Among the various potential routes of 
immunization, the transcutaneous and nasal routes aroused considerable interest, 
particularly due to their amenability for non-invasive delivery of vaccines. 
Most of the currently studied polymeric NPs, such as PLGA and PLA, suffer from 
multiple limitations. Among them can be mentioned the use of chemical solvents 
and physical stresses during the production process, which negatively affect 
antigen stability, and the involvement of complex multistep processes to generate 
them [118]. In the present work we overcome some of the problems described 
above, by using a simple approach based on inverse micelles. IMSG NPs were 
prepared using pharmaceutical excipients which are GRAS (generally regarded as 
safe) listed, and possess biocompatible and biodegradable properties. 
Furthermore, antigen encapsulated in IMSG NPs turned out to be much more 
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biological active (85 ± 5%) using ELISA in comparison to previously described 
antigen-loaded Chitosan-PLGA NPs (65 ± 5%) [12].  
We evaluated the antigen delivery efficacy of our novel particulate system (IMSG 
NPs) by immunizing mice via three different routes (IN, ID and TF). To this end, 
we firstly evaluated the performance of OVA encapsulated IMSG NPs over OVA 
solution and the previously evaluated OVA-loaded Chit-PLGA NPs for TF delivery. 
We observed a significantly (p<0.001) higher follicular uptake of OVA 
encapsulated IMSG NPs compared to OVA solution and OVA-loaded Chit-PLGA 
NPs (Fig. 3). This is in line with previous results obtained by Raber et al. who 
showed that penetration of nanoparticles into hair follicles is material dependent 
[124]. Moreover, we observed strong induction of OVA-specific T cells proliferation 
by IMSG NPs in comparison to the previously evaluated OVA-loaded Chit-PLGA 
NPs [12] using an adoptive T cell transfer mouse model (Fig. 4).  
In case of the ID route, recent studies showed that ID delivery of antigen is more 
efficient in stimulating antigen-specific immune responses compared to 
intramuscular injection, even using low antigenic doses [125]. This is further 
supported by data from Bal et al. showing the beneficial effect of delivering antigen 
using nanoparticles via ID route [65]. Our data demonstrated that similar results 
can be obtained using IMSG NPs. Furthermore, immunization with OVA and c-di-
AMP co-encapsulated IMSG NPs significantly increased OVA-specific IgG titers. 
The enhanced humoral response most likely is based on the combination of the 
strong adjuvant activity of c-di-AMP and the depot effect created by the oily 
character of the IMSG NPs-based system, which in turn ensures antigen and 
adjuvant release in a sustained manner. Furthermore, co-encapsulation of 
adjuvant in the NPs significantly boosted the production of the IgG2c subclass, 
thereby indicating an enhanced Th1 response. In contrast, administration of OVA-
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encapsulated NPs or soluble OVA admixed with c-di-AMP does not significantly 
affect the polarization of the antigen-stimulated Th response. This is in line with 
previous observations demonstrating that co-encapsulation of antigen and 
adjuvant in the same NPs is crucial for a potent immune response due to 
concomitant delivery of antigen and adjuvant to the same APC [42, 123, 126]. 
Interestingly, although TF vaccination with OVA + c-di-AMP co-encapsulated in 
IMSG NPs also promoted strong OVA-specific IgG responses, no shift towards a 
more balanced Th1/Th2 response was observed. This might be explained by the 
interaction of IMSG NPs with different APCs at the different anatomic niches. In 
the epidermal area of the hair follicle canal mainly langerhans cells (LCs) are 
resident, whereas the dermal area is populated by dermal DCs [127]. Both DC 
subsets where shown to be able to stimulate different, if not opposing, adaptive 
immune responses. This is not only based on the cytokines produced by these 
cells following interaction with the antigen and/or adjuvant, but also due 
differences in their intrinsic properties, such as cross-presentation [128]. Further 
studies are needed to elucidate the underlying mechanisms, but several aspects 
such as miscibility of oil components with sebum and pH gradient might play a 
significant role. However, IN delivery of OVA-loaded IMSG NPs with or without co-
encapsulation of c-di-AMP generated only poor antibody responses, if any at all. 
Presumably, oil viscosity hindered the delivery of antigen and adjuvants through 
the nasal epithelium. Interestingly, in contrast to what was observed following ID 
and TF immunization, only mice receiving OVA + c-di-AMP solution via IN route 
showed increased levels of IgG2c. These results are in line with previous studies 
showing that co-administration of antigens (OVA as well as vaccine antigens) c-di-
AMP by IN route triggers an efficient and balanced Th1/Th2/Th17 response [95]. 
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T cell-mediated immunity is a central element of the adaptive immune system, 
which is needed to eliminate pathogens or malignant cells. Thus, we evaluated 
cellular immune responses following immunization with IMSG NP-based 
formulations by different routes. Consistent with the humoral responses stimulated 
after vaccination via ID and TF route, OVA and c-di-AMP co-encapsulated within 
IMSG NPs stimulated the strongest cellular responses, both at local and systemic 
level. In contrast, when mice were immunized via IN route using this formulation, 
increased proliferative capacity of antigen-specific cells was only observed at local 
level. However, this cellular response was significantly weaker compared to that 
stimulated by soluble OVA admixed with c-di-AMP. Nevertheless, when the 
cytokine profiles of antigen-restimulated cells were analyzed, increased levels of 
cytokines (e.g. IFN) were detected in the group receiving OVA and c-di-AMP co-
encapsulated IMSG NPs and OVA + c-di-AMP solution. This suggests that despite 
the fact that the overall immunogenicity of the IMSG NP-based formulation was 
rather modest, it was sufficient for priming. Furthermore, adjuvantation with c-di-
AMP seems to be essential to stimulate IFN production. Nevertheless, the 
concurrent expression of the Th1 associated cytokine IFN and the Th2 associated 
cytokines IL-5 and IL-13 indicate a balanced Th1/Th2 response, which is in line 
with the observed IgG subclass profiles. Interestingly, TF immunization also 
resulted in enhanced expression of IL-17, whereas vaccination via ID route did 
not. This is consistent with observations by Igyártó et al. showing that epidermis 
resident LCs promote the stimulation of Th17 cells, whereas dermis resident DCs 
rather stimulate Th1 responses and inhibit Th17 differentiation [128]. While Th17 
responses were shown to play an important role in host protection against 
extracellular pathogens (e.g. bacteria and fungi), Th1 responses are needed to 
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efficiently protect against intracellular bacterial and viral infections (reviewed in 
[129, 130].  
Vaccination using IMSG NPs seems to stimulate only strong CD4+ T helper 
responses, since only marginal activation of antigen-specific CD8+ T cells could 
be observed. Most likely this failure is based on the oily nature of the formulations, 
as similar observations were made with Freund´s incomplete adjuvant (IFA, a 
water-in-oil emulsion), as well as with oil-in-water emulsions (e.g. MF59 and AS03) 
[131]. IFA is one of the most commonly used adjuvants in research and is 
prepared from non-metabolizable oils (paraffin oil and mannide monooleate), 
whereas MF59 and AS03 adjuvants encompass squalene, one of the most 
common lipids produced by human skin cells, forming oil-in-water nano-emulsions 
made up of <250 nm droplets [131, 132]. Both types of adjuvants preferentially 
polarize the T cell response towards a functional Th2 phenotype by a yet unknown 
mechanism [133]. Possible explanations can be (i) a depot effect, (ii) enhanced 
antigen uptake by DCs and (iii) altered cellular lipid metabolism [134-136]. In case 
of IFA, it has been suggested that NOD2, an intracellular pattern recognition 
receptor recognizing bacterial component, modulates the adjuvanticity of IFA 
[137]. Incorporation of a potent CD8+ stimulating adjuvant might favor stimulation 
of IFN producing CD8+ by IMSG NPs-based formulations. Antigen concentration 
could be also optimized, since Ebensen et al. showed efficient stimulation of 
cytotoxic T cells after IN immunization by increasing the OVA dosage [95].  
There is a consensus that efficient protection against infection not only depends 
on the number of antigen-specific T cells but also on their functional properties. T 
cells which produce several cytokines at the time are more potent as compared to 
single producers [98]. In this regard, the quality of the T helper response 
stimulated using OVA and c-di-AMP co-encapsulated IMSG NPs was significantly 
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improved. OVA and c-di-AMP co-encapsulated in IMSG NPs stimulated the 
highest values of bi- and tri-functional CD4+ T cells following ID and TF 
immunization. Interestingly, also IN vaccination resulted in the stimulation of 
multifunctional CD4+ cells, although to a lesser extent compared to the adjuvanted 
OVA solution. This is particularly important considering that in some infections 
stimulation of multifunctional CD4+ T cells seems to be even more critical than 
activation of CD8+ T cells to confer protection [114, 115]. 
 
4.6. Conclusion 
The results presented in this study showed IMSG NPs as a unique delivery system 
with enhance protein encapsulating efficacy and stability. Moreover, co-
encapsulation of an adjuvant inside the particles resulted in enhanced humoral 
and cellular immune responses both at local and systemic level when mice were 
immunized by ID or TF route. Immunization of mice with OVA + c-di-AMP co-
encapsulated in IMSG NPs also stimulated strong antigen-specific multifunctional 
CD4+ T helper responses with bi- and tri-functional capacity.  Thus, IMSG NPs 
constitute a promising delivery system for the establishment of ID and TF 
vaccination strategies. 
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5. Overall Conclusion and Outlook  
The major aim of this thesis was to highlight the potential of transfollicular delivery 
of a model antigen (ovalbumin) using nanoparticles based delivery systems 
without pre-treating the skin for non-invasive transcutaneous vaccination. 
Nanoparticles (NPs) are the ideal vehicles for transfollicular delivery as they 
accumulate in hair follicles and skin folds and penetrate deeper into hair follicles 
than molecules in solution. In literature, vaccination via the transfollicular pathway 
using NPs has been shown to generate effective immune responses, however 
much of this work was conducted after pretreating the skin area in various ways 
such as by plucking the hairs, waxing, or cyanoacrylate (superglue) stripping. As a 
result of pre-treatment, the stratum corneum is (at least partially) removed, 
meaning that it is not clear to which extent the antigen penetrates via the hair 
follicles or across the permeabilized stratum corneum. In contrast, the results 
reported here have demonstrated the potential of NPs to deliver antigen and 
adjuvant via the transfollicular route without pre-treating the skin. Furthermore, we 
have demonstrated the significance of nanoparticulate delivery systems in 
influencing the immune response generated via this vaccination pathway, thus 
providing a platform to support rational design of vaccines combining antigen and 
adjuvants in a particulate system in order to generate efficient immune responses 
and create safe vaccines.  
 
 As was shown in the first section of this thesis, immune responses can be 
generated via the transfollicular route without disrupting the stratum 
corneum barrier by using polymeric NPs. This was demonstrated by in vitro 
and in vivo experiments. Firstly, the efficacy of polymeric NPs (polylactic-
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co-glycolide (PLGA) and Chitosan-PLGA NPs) in enhancing follicular 
uptake of ovalbumin (OVA) in comparison to OVA solution was tested using 
an in vitro pig ear model. A 2-3 fold enhancement in follicular uptake was 
observed when antigen was encapsulated into NPs. Moreover, in a cell 
culture assay, the ability of NPs to stimulate proliferation of OVA-specific T 
cells in comparison to OVA in solution was evaluated. An enhanced 
proliferation of OVA-specific T cells (CD4+ T cells) was observed when 
antigen was encapsulated into NPs. However, only OVA-loaded Chitosan-
PLGA NPs were able to stimulate proliferation of CD8+ T cells to a large 
extent in comparison to OVA in solution. Secondly, by in vivo experiments 
using an adoptive transfer model, we could show generation of immune 
responses by the transfollicular route using OVA-loaded Chitosan-PLGA 
NPs. Moreover, the immune response generated by OVA-loaded NPs 
following transfollicular administration was able to elicit the same 
proliferation of OVA-specific CD4+ T cells as an intramuscular injection of 
OVA.  
 
 As the adoptive transfer experiment showed the viability of the 
transfollicular route, an extensive characterization of the immune responses 
generated by this route was further required. Therefore, in the second 
section of this thesis, in vivo mouse studies were extended to a normal 
vaccination setting (conventional mice) to confirm the viability of the 
transfollicular route, as well as to obtain deeper insights into the immune 
responses generated using antigen-loaded Chitosan-PLGA NPs without 
skin pre-treatment. Additionally, we tested the integrity of skin using 
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transepidermal water loss (TEWL) measurements before and after 
depilation and for the following 2 days to ensure skin integrity before 
applying formulations on skin. Interestingly, we found that TEWL 
measurements 30 min after depilation were double those of the normal 
untreated skin; a return to baseline levels, as recorded before depilation, 
was however seen within 2 days, indicating a full recovery. Moreover, 
immune responses generated by applying different formulations (OVA 
loaded Chitosan-PLGA NPs and OVA solution) on tape stripped and intact 
skin were also compared. Furthermore, immune responses generated by 
applying antigen-loaded NPs on untreated skin in the presence (co-
admixed) or absence of an adjuvant (bis-(3',5')-cyclic dimeric adenosine 
monophosphate (c-di-AMP)) were characterized. We could show from our 
in vivo studies that inclusion of an adjuvant is necessary in the formulation 
along with nanoparticulate system in order to generate both efficient 
antigen-specific humoral as well as cellular immune responses based on 
multifunctional CD4+ and CD8+ T cells when no pre-treatment was applied 
on skin.  
 Preparation of Chitosan-PLGA NPs by the emulsion-diffusion-evaporation 
method involves multiple steps with use of chemical solvents and physical 
stresses during the production process that may negatively affect antigen 
stability. Therefore, we planned to fabricate a new particulate system with (i) 
enhanced stability of the encapsulated protein; (ii) simplified preparation 
method; (iii) co-encapsulation of adjuvant and antigen in the same system 
(as in literature, co-encapsulation of antigen and adjuvant in the same NPs 
has been shown to generate better immune response due to concomitant 
delivery of antigen and adjuvant to the same dendritic cells (DCs)); (iv) 
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enhanced follicular uptake; and (v) ease of formulation applicability on skin. 
These points motivated us to perform the studies described in the third 
section of this thesis. Inverse micellar sugar glass NPs were prepared using 
an inverse micellar technique and pharmaceutically accepted excipients 
(surfactants, sugars and oil, GRAS (generally regarded as safe) listed) and 
characterized for efficient incorporation and stabilization of antigen. At first, 
we tested the integrity and stability of the encapsulated antigen, OVA, using 
SDS PAGE and ELISA and compared these results with previously 
prepared Chitosan-PLGA NPs. Moreover, we compared follicular uptake 
efficacy and immune responses generated by inverse micellar sugar glass 
NPs with Chitosan-PLGA NPs in vitro using a pig ear model, and in vivo 
using an adoptive transfer mouse model. We observed superiority of 
inverse micellar sugar glass NPs in terms of stabilization of the 
encapsulated antigen, delivery of antigen into hair follicles and proliferation 
of antigen-specific T cells in comparison to antigen loaded Chitosan-PLGA 
NPs. Next, we evaluated the immune response generated by inverse 
micellar sugar glass NPs with or without adjuvant in a conventional mouse 
model after transfollicular application. Moreover, we tested inverse micellar 
sugar glass NPs delivered intranasally and intradermally, in order to study 
the effectiveness of this formulation when administered via other routes. In 
the case of intranasal delivery, no or low immune response was generated, 
presumably due to the viscosity of the oil component of the formulation, 
which hindered the delivery of antigen and adjuvants through the nasal 
epithelium. This showed that such a delivery system is not suitable for 
application via the nasal route. Interestingly, in case of the intradermal 
route, OVA-loaded sugar glass NPs generated similar humoral response 
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compared to OVA protein co-administered with c-di-AMP indicating the 
beneficial effect of NPs. Moreover, enhanced humoral and cellular 
responses both at local and systemic level were observed when OVA + c-di 
AMP loaded NPs were administered. In case of transfollicular route, 
enhanced humoral and cellular response were also observed in mice 
immunized with OVA + c-di AMP loaded NPs. However, immune responses 
generated by transfollicular vaccination were less strong in comparison to 
intradermal vaccination. These data further support the inherent potential of 
transfollicular vaccination in conjunction with nanotechnology, but also 
showed the need to further optimize the carrier technology to achieve a 
robust immune response. In summary, inverse micellar sugar glass NPs 
constitute a promising delivery system for the establishment of intradermal 
and transfollicular vaccination strategies. 
 
Suggestions for Future work:  
 
Based on our studies so far, vaccination via the transfollicular route holds the 
potential to generate effective immune responses for the development of patient-
compliant, needle-free, safe vaccines. However, the major challenge is to deliver 
antigen to peri-follicular antigen presenting cells in order to generate an efficient 
immune response. Results from this thesis have shown the potential of 
nanoparticulate systems to deliver antigen to the peri-follicular region; at the same 
time however, it has been demonstrated that it is necessary to include an adjuvant 
in such nanoparticulate formulations to modulate the immune response via 
transfollicular route. Future work should focus on i) mechanistic studies for better 
understanding the translocation as well as uptake mechanism of the antigen 
and/or adjuvant by antigen presenting cells after transfollicular application, ii) 
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validation studies using disease relevant antigens (e.g. influenza virus antigens, 
hepatitis C virus) in mouse as well as other pre-clinical models, and iii) further 
development in terms of fabrication of particulate systems for transfollicular 
delivery. Although the particulate systems studied in this thesis showed improved 
transfollicular delivery and enhanced immune responses in comparison to OVA 
solution, further modifications of the studied systems or in fact new particulate 
system could enhance the effectiveness of this approach. These efforts should 
focus on i) improving the targeting efficacy of NPs to the hair follicle as large 
amount of NPs (~90%) were lost on the skin surface or during application, and ii) 
optimizing nanoparticulate systems with a special focus on studies of the impact of 
adjuvant type and degree of NP association (co-mixed, NP surface decorated or 
co-encapsulated). Such studies would lead to the development of a more robust 
delivery system. 
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6. List of Abbreviations 
APCs Antigen presenting cells 
BSA Bovine serum albumin 
CD 4 or CD 8 Clusters of differentiation (4 or 8) 
CFSE Carboxyfluoresceine succinimidyl ester 
Chit-PLGA Chitosan-PLGA 
CPM Counts per minute 
DCs Dendritic cells 
ELISA Enzyme linked Immuno assay 
FACS Fluorescence activated cell sorting  
FITC Fluorescein isothiocynate  
GRAS Generally regarded as safe 
I.D. Intradermal 
I.N. Intranasal 
IFN Interferon gamma 
IL Interleukin 
IMSG NPs Inverse micellar sugar glass nanoparticles 
LCs Langerhans cells 
LPS Lipopolysaccharide  
MCT Medium chain triglycerides 
MPs Microparticles 
NALT Nasal associated lymphoid tissue 
NPs Nanoparticles 
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OVA Ovalbumin 
PBS Phosphate buffer saline 
PDI Polydispersity index 
PLGA Poly lactide-co-glcolide 
PVA Polyvinyl alcohol 
RPMI Roswell Park Memorial Medium 
SC Stratum corneum 
SD Standard deviation 
SDS PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM Scanning electron microscopy 
SEM Standard error mean 
SI Stimulation Index 
T.F. Transfollicular 
TCI Transcutaneous Immunization 
TCV Transcutaneous vaccination 
TEM Transmission electron microscopy 
TEWL Transepidermal water loss 
Th1 / Th2 T helper cells (1 or 2) 
TNFα Tumor necrosis factor-alpha 
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